Dan Roden

Q: What Schools Are Affiliated With Dan Roden

Dan Roden is affiliated with the following schools: Boston University, Niigata University, Utah State University, University of Pavia, Vanderbilt University, University of Chicago, Leipzig University

Dan Roden's AcademicInfluence.com Rankings

Dan Roden

Medical

#488

World Rank

#664

Historical Rank

#194

USA Rank

Pharmacology

#37

World Rank

#50

Historical Rank

#16

USA Rank

medical Degrees

Dan Roden

Philosophy

#2576

World Rank

#4362

Historical Rank

#906

USA Rank

Logic

#653

World Rank

#1146

Historical Rank

#240

USA Rank

philosophy Degrees

Download Badge

Medical
Philosophy

Dan Roden's Degrees

Doctorate Medicine University of Chicago
PhD Pharmacology University of Chicago

Why Is Dan Roden Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Dan Roden is a Canadian-born American medical researcher known for his work in personalized medicine. He is Professor of Medicine, Pharmacology and Biomedical Informatics at the Vanderbilt University School of Medicine, where he holds the Sam L. Clark Endowed Chair and serves at the Senior Vice President for Personalized Medicine. He is also the director of Vanderbilt University's BioVU project, which is a biobank linking individuals' DNA samples to their medical records.

(See a Problem?)

Dan Roden's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (2006) (2558)
Estimation of the warfarin dose with clinical and pharmacogenetic data. (2009) (1522)
Fulminant Myocarditis with Combination Immune Checkpoint Blockade. (2016) (1389)
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. (1998) (1106)
PheWAS: demonstrating the feasibility of a phenome-wide scan to discover gene–disease associations (2010) (893)
Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program (2019) (785)
Systematic comparison of phenome-wide association study of electronic medical record data and genome-wide association study data (2013) (763)
Drug-induced prolongation of the QT interval. (2004) (711)
Taking the “Idio” out of “Idiosyncratic”: Predicting Torsades de Pointes (1998) (668)
The eMERGE Network: A consortium of biorepositories linked to electronic medical records data for conducting genomic studies (2011) (665)
Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. (1996) (654)
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. (2010) (633)
The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future (2013) (596)
Genetic determinants of response to warfarin during initial anticoagulation. (2008) (581)
Allelic Variants in Long-QT Disease Genes in Patients With Drug-Associated Torsades de Pointes (2002) (562)
Sudden Cardiac Death Prediction and Prevention: Report From a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop (2010) (555)
Flecainide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans (2009) (555)
Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. (2018) (549)
Meta-analysis identifies six new susceptibility loci for atrial fibrillation (2012) (535)
A common polymorphism associated with antibiotic-induced cardiac arrhythmia. (2000) (487)
[Guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Executive summary]. (2006) (485)
Incidence and clinical features of the quinidine-associated long QT syndrome: implications for patient care. (1986) (483)
Sodium channel β1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. (2008) (481)
A sequence variant in ZFHX3 on 16q22 associates with atrial fibrillation and ischemic stroke (2009) (466)
Implementing genomic medicine in the clinic: the future is here (2013) (463)
Cardiac ion channels. (2002) (459)
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. (2008) (455)
Common Variants in KCNN3 are Associated with Lone Atrial Fibrillation (2010) (454)
Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death (2013) (441)
Casq2 deletion causes sarcoplasmic reticulum volume increase, premature Ca2+ release, and catecholaminergic polymorphic ventricular tachycardia. (2006) (437)
Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. (1996) (432)
Exome-wide association study of plasma lipids in >300,000 individuals (2017) (428)
Multi-ethnic genome-wide association study for atrial fibrillation (2018) (425)
Interrelationship Between Substrates and Inhibitors of Human CYP3A and P-Glycoprotein (1999) (422)
Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine [seecomments]. (1999) (410)
A structural variation reference for medical and population genetics (2020) (394)
Metabolic Syndrome and Risk of Development of Atrial Fibrillation: The Niigata Preventive Medicine Study (2008) (389)
[ACC/AHA/ESC 2006 guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary]. (2006) (378)
Action Potential Prolongation and Induction of Abnormal Automaticity by Low Quinidine Concentrations in Canine Purkinje Fibers Relationship to Potassium and Cycle Length (1985) (361)
Drugs and Brugada syndrome patients: review of the literature, recommendations, and an up-to-date website (www.brugadadrugs.org). (2009) (351)
Incorporation of Pharmacogenomics into Routine Clinical Practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline Development Process (2014) (346)
Clinical practice. Long-QT syndrome. (2008) (336)
The long QT syndromes: genetic basis and clinical implications. (2000) (332)
Drug‐Induced Torsades de Pointes and Implications for Drug Development (2004) (330)
Cardiac Sodium Channel (SCN5A) Variants Associated with Atrial Fibrillation (2008) (325)
Transgenic Mice Overexpressing Mutant PRKAG2 Define the Cause of Wolff-Parkinson-White Syndrome in Glycogen Storage Cardiomyopathy (2003) (323)
Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record. (2010) (316)
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. (2016) (309)
Genetic and molecular basis of cardiac arrhythmias: impact on clinical management parts I and II. (1999) (309)
Long QT syndrome: reduced repolarization reserve and the genetic link (2006) (307)
A rare variant in MYH6 is associated with high risk of sick sinus syndrome (2011) (294)
Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation. (2010) (291)
Polymorphism of propafenone metabolism and disposition in man: clinical and pharmacokinetic consequences. (1987) (290)
Inactivating mutations in NPC1L1 and protection from coronary heart disease. (2014) (289)
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges (2007) (286)
PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study (2017) (283)
Close bidirectional relationship between chronic kidney disease and atrial fibrillation: the Niigata preventive medicine study. (2008) (282)
Calmodulin Kinase II and Arrhythmias in a Mouse Model of Cardiac Hypertrophy (2002) (279)
Genetics of acquired long QT syndrome. (2005) (262)
The genetic basis of variability in drug responses (2002) (261)
Genetic association study of QT interval highlights role for calcium signaling pathways in myocardial repolarization (2014) (260)
PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability (2016) (255)
Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing (2013) (255)
KCNH2-K897T Is a Genetic Modifier of Latent Congenital Long-QT Syndrome (2005) (250)
Nkx2-5 mutation causes anatomic hypoplasia of the cardiac conduction system. (2004) (249)
Variants near FOXE1 are associated with hypothyroidism and other thyroid conditions: using electronic medical records for genome- and phenome-wide studies. (2011) (248)
Molecular cloning and characterization of two voltage‐gated K+ channel cDNAs from human ventricle (1991) (244)
The Lambeth Conventions (II): guidelines for the study of animal and human ventricular and supraventricular arrhythmias. (2013) (244)
ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death--executive summary: A report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidel (2006) (244)
Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation (2017) (243)
Drug-Induced Long QT Syndrome (2010) (237)
The phenotypic legacy of admixture between modern humans and Neandertals (2016) (235)
A calcium sensor in the sodium channel modulates cardiac excitability (2002) (235)
Common Sodium Channel Promoter Haplotype in Asian Subjects Underlies Variability in Cardiac Conduction (2006) (234)
When good drugs go bad (2007) (233)
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study (2013) (232)
Drug-induced long QT and torsade de pointes: recent advances (2007) (230)
Mutations in Sodium Channel β1- and β2-Subunits Associated With Atrial Fibrillation (2009) (228)
Recovery of trait heritability from whole genome sequence data (2019) (223)
Large scale replication and meta-analysis of variants on chromosome 4q25 associated with atrial fibrillation. (2008) (219)
The E1784K mutation in SCN5A is associated with mixed clinical phenotype of type 3 long QT syndrome. (2008) (216)
The T-Box transcription factor Tbx5 is required for the patterning and maturation of the murine cardiac conduction system (2004) (215)
Replacement by homologous recombination of the minK gene with lacZ reveals restriction of minK expression to the mouse cardiac conduction system. (1999) (211)
Evaluating phecodes, clinical classification software, and ICD-9-CM codes for phenome-wide association studies in the electronic health record (2017) (205)
Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease (2017) (204)
Congenital and acquired long QT syndrome. (2000) (200)
Cardiac potassium channel dysfunction in sudden infant death syndrome. (2007) (199)
Phenotypic Variability and Unusual Clinical Severity of Congenital Long-QT Syndrome in a Founder Population (2005) (199)
Genome-wide association study identifies a susceptibility locus at 21q21 for ventricular fibrillation in acute myocardial infarction (2010) (198)
Design and Anticipated Outcomes of the eMERGE-PGx Project: A Multi-Center Pilot for Pre-Emptive Pharmacogenomics in Electronic Health Record Systems (2014) (196)
Principles of Human Subjects Protections Applied in an Opt‐Out, De‐identified Biobank (2010) (195)
Mice with the R176Q cardiac ryanodine receptor mutation exhibit catecholamine-induced ventricular tachycardia and cardiomyopathy (2006) (191)
Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone. (1991) (189)
Ibutilide, a methanesulfonanilide antiarrhythmic, is a potent blocker of the rapidly activating delayed rectifier K+ current (IKr) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects. (1995) (185)
Inherited Causes of Clonal Hematopoiesis in 97,691 TOPMed Whole Genomes (2020) (184)
Global implementation of genomic medicine: We are not alone (2015) (183)
Predictive Accuracy of a Polygenic Risk Score Compared With a Clinical Risk Score for Incident Coronary Heart Disease. (2020) (181)
Total suppression of ventricular arrhythmias by encainide. Pharmacokinetic and electrocardiographic characteristics. (1980) (179)
Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality (2014) (179)
Rapid inactivation determines the rectification and [K+]o dependence of the rapid component of the delayed rectifier K+ current in cardiac cells. (1997) (178)
Defining the Cellular Phenotype of “Ankyrin-B Syndrome” Variants: Human ANK2 Variants Associated With Clinical Phenotypes Display a Spectrum of Activities in Cardiomyocytes (2007) (174)
Normalization of acquired QT prolongation in humans by intravenous potassium. (1997) (173)
Drug Block of I Kr : Model Systems and Relevance to Human Arrhythmias (2001) (172)
Phenome-Wide Association Studies as a Tool to Advance Precision Medicine. (2016) (170)
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Overcoming Challenges of Real‐World Implementation (2013) (166)
Genome- and Phenome-Wide Analyses of Cardiac Conduction Identifies Markers of Arrhythmia Risk (2013) (163)
Congenital long-QT syndrome caused by a novel mutation in a conserved acidic domain of the cardiac Na+ channel. (1999) (163)
Cardiac-specific overexpression of AT1 receptor mutant lacking Gαq/Gαi coupling causes hypertrophy and bradycardia in transgenic mice (2005) (163)
Pharmacogenomics: Challenges and Opportunities (2006) (162)
Antiarrhythmic efficacy, pharmacokinetics and safety of N-acetylprocainamide in human subjects: comparison with procainamide. (1980) (158)
Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. (1981) (156)
A Large Candidate Gene Survey Identifies the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes (2012) (156)
Association of Arrhythmia-Related Genetic Variants With Phenotypes Documented in Electronic Medical Records. (2016) (155)
Blocking Scn10a Channels in Heart Reduces Late Sodium Current and Is Antiarrhythmic (2012) (154)
Prospective, population-based long QT molecular autopsy study of postmortem negative sudden death in 1 to 40 year olds. (2011) (153)
Mexiletine in the Treatment of Resistant Ventricular Arrhythmias: Enhancement of Efficacy and Reduction of Dose‐related Side Effects by Combination with Quinidine (1983) (152)
A K+ Channel Splice Variant Common in Human Heart Lacks a C-terminal Domain Required for Expression of Rapidly Activating Delayed Rectifier Current* (1998) (152)
Pharmacogenomics: The Genetics of Variable Drug Responses (2011) (151)
Drug therapy. Flecainide. (1986) (151)
Genome-wide association studies in pharmacogenomics: successes and lessons (2013) (150)
Phenotype risk scores identify patients with unrecognized Mendelian disease patterns (2018) (147)
Genetic and molecular basis of cardiac arrhythmias: impact on clinical management part III. (1999) (145)
Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology. (1999) (145)
Cardiac repolarization: current knowledge, critical gaps, and new approaches to drug development and patient management. (2002) (144)
Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment. (2020) (133)
Predicting drug‐induced QT prolongation and torsades de pointes (2016) (133)
Striking In Vivo Phenotype of a Disease-Associated Human SCN5A Mutation Producing Minimal Changes in Vitro (2011) (133)
Identification of Genomic Predictors of Atrioventricular Conduction: Using Electronic Medical Records as a Tool for Genome Science (2010) (133)
Screening for Acute IKr Block Is Insufficient to Detect Torsades de Pointes Liability: Role of Late Sodium Current (2014) (132)
Relation of the severity of obstructive sleep apnea in response to anti-arrhythmic drugs in patients with atrial fibrillation or atrial flutter. (2012) (131)
The role of genetically determined polymorphic drug metabolism in the beta-blockade produced by propafenone. (1990) (130)
A genome- and phenome-wide association study to identify genetic variants influencing platelet count and volume and their pleiotropic effects (2013) (130)
Symptomatic response to antiarrhythmic drug therapy is modulated by a common single nucleotide polymorphism in atrial fibrillation. (2010) (129)
Cardiovascular Toxicities Associated With Ibrutinib. (2019) (129)
Quinidine delays IK activation in guinea pig ventricular myocytes. (1988) (127)
Pharmacogenomics (2019) (125)
Pharmacogenetics and drug-induced arrhythmias. (2001) (124)
Mechanisms and management of proarrhythmia. (1998) (123)
Virtual cathode effects during stimulation of cardiac muscle. Two-dimensional in vivo experiments. (1991) (123)
Risks and benefits of antiarrhythmic therapy. (1994) (120)
Inherited Long QT Syndromes: (1999) (120)
Casq 2 deletion causes sarcoplasmic reticulum volume increase , premature Ca 2 + release , and catecholaminergic polymorphic ventricular tachycardia (2006) (119)
Drug-Sensitized Zebrafish Screen Identifies Multiple Genes, Including GINS3, as Regulators of Myocardial Repolarization (2009) (118)
Time-dependent outward current in guinea pig ventricular myocytes. Gating kinetics of the delayed rectifier (1990) (118)
Repolarization reserve: a moving target. (2008) (116)
Calmodulin kinase inhibition prevents development of the arrhythmogenic transient inward current. (1999) (114)
Delayed radiation injury to the retrobulbar optic nerves and chiasm. Clinical syndrome and treatment with hyperbaric oxygen and corticosteroids. (1990) (114)
Biobanks and Electronic Medical Records: Enabling Cost-Effective Research (2014) (114)
Role of common and rare variants in SCN10A: results from the Brugada syndrome QRS locus gene discovery collaborative study. (2015) (113)
Stereoselective disposition and pharmacologic activity of propafenone enantiomers. (1989) (112)
Desiderata for computable representations of electronic health records-driven phenotype algorithms (2015) (111)
Current status of class III antiarrhythmic drug therapy. (1993) (110)
Variation in the 4q25 Chromosomal Locus Predicts Atrial Fibrillation After Coronary Artery Bypass Graft Surgery (2009) (110)
Unmasking of Brugada Syndrome by Lithium (2005) (110)
Differential expression of KvLQT1 and its regulator IsK in mouse epithelia. (2001) (107)
Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. (2012) (106)
Association Between Titin Loss-of-Function Variants and Early-Onset Atrial Fibrillation (2018) (106)
A KCNJ8 mutation associated with early repolarization and atrial fibrillation. (2012) (105)
Protecting the heart against arrhythmias: potassium current physiology and repolarization reserve. (2005) (104)
Genetics of glucocorticoid-associated osteonecrosis in children with acute lymphoblastic leukemia. (2015) (104)
Suppression of repolarization-related arrhythmias in vitro and in vivo by low-dose potassium channel activators. (1990) (103)
Influence of genetic polymorphism on the metabolism and disposition of encainide in man. (1984) (102)
Electronic health record design and implementation for pharmacogenomics: a local perspective (2013) (101)
Acquired Long QT Syndromes and the Risk of Proarrhythmia (2000) (100)
Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record. (2012) (100)
Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial (2017) (100)
Genetics and Cardiovascular Disease: A Policy Statement From the American Heart Association (2012) (98)
Anti-minK antisense decreases the amplitude of the rapidly activating cardiac delayed rectifier K+ current. (1995) (97)
Performant Mutation Identification Using Targeted Next‐Generation Sequencing of 14 Thoracic Aortic Aneurysm Genes (2015) (96)
Polymorphism modulates symptomatic response to antiarrhythmic drug therapy in patients with lone atrial fibrillation. (2007) (96)
Unusual Effects of a QT-Prolonging Drug, Arsenic Trioxide, on Cardiac Potassium Currents (2003) (95)
Systemic administration of calmodulin antagonist W-7 or protein kinase A inhibitor H-8 prevents torsade de pointes in rabbits. (1999) (95)
Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. (2011) (95)
Potassium current antagonist properties and proarrhythmic consequences of quinolone antibiotics. (2001) (94)
Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects (2018) (93)
Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large whole genome sequencing studies at scale (2020) (93)
Defective Human Ether-à-go-go-related Gene Trafficking Linked to an Endoplasmic Reticulum Retention Signal in the C Terminus* (2002) (93)
Phenotypic Refinement of Heart Failure in a National Biobank Facilitates Genetic Discovery (2019) (92)
Bedside Back to Bench: Building Bridges between Basic and Clinical Genomic Research (2017) (92)
Concentration-dependent pharmacologic properties of sotalol. (1986) (92)
Common atrial fibrillation risk alleles at 4q25 predict recurrence after catheter-based atrial fibrillation ablation. (2013) (91)
Common Genetic Variants and Response to Atrial Fibrillation Ablation (2015) (91)
Early after-depolarizations and torsade de pointes: implications for the control of cardiac arrhythmias by prolonging repolarization. (1993) (91)
Drug therapy : propafenone (1990) (90)
Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation. (2010) (90)
A genetic framework for improving arrhythmia therapy (2008) (90)
Transcript expression-aware annotation improves rare variant interpretation (2020) (89)
Cardiac-specific overexpression of AT1 receptor mutant lacking G alpha q/G alpha i coupling causes hypertrophy and bradycardia in transgenic mice. (2005) (88)
Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. (2015) (88)
Effects of low potassium or magnesium concentrations on isolated cardiac tissue. (1987) (88)
Common genetic polymorphism at 4q25 locus predicts atrial fibrillation recurrence after successful cardioversion. (2013) (87)
Cardiovascular Toxicities Associated With Hydroxychloroquine and Azithromycin (2020) (87)
Clopidogrel and the Concept of High-Risk Pharmacokinetics (2009) (86)
Evaluating drug targets through human loss-of-function genetic variation (2019) (86)
Voltage-Gated Sodium Channels Are Required for Heart Development in Zebrafish (2010) (85)
Assessing the accuracy of observer-reported ancestry in a biorepository linked to electronic medical records (2010) (84)
Block of IKs, the slow component of the delayed rectifier K+ current, by the diuretic agent indapamide in guinea pig myocytes. (1994) (84)
Mapping and characterization of structural variation in 17,795 human genomes (2020) (84)
Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment (2020) (84)
Modification of Proteins by Isoketal-containing Oxidized Phospholipids* (2004) (83)
Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. (2009) (83)
Chromosome 4q25 variants are genetic modifiers of rare ion channel mutations associated with familial atrial fibrillation. (2012) (82)
Identifying genetic risk factors for serious adverse drug reactions: current progress and challenges (2008) (82)
Gating-Dependent Mechanisms for Flecainide Action in SCN5A-Linked Arrhythmia Syndromes (2001) (82)
Atrial Fibrillation in KCNE1-Null Mice (2005) (81)
Amiodarone dosing: a proposal based on its pharmacokinetics. (1983) (81)
Genetic determinants of risk in pulmonary arterial hypertension: international genome-wide association studies and meta-analysis (2019) (81)
Clinical features and basic mechanisms of quinidine-induced arrhythmias. (1986) (81)
Phenome-wide scanning identifies multiple diseases and disease severity phenotypes associated with HLA variants (2017) (80)
Anticancer drug‐induced cardiac rhythm disorders: Current knowledge and basic underlying mechanisms (2018) (80)
Calmodulin Inhibitor W-7 Unmasks a Novel Electrocardiographic Parameter That Predicts Initiation of Torsade de Pointes (2002) (80)
Structure and function of cardiac sodium and potassium channels. (1997) (79)
Cisapride‐Induced Torsades de Pointes (1998) (79)
Genetic mechanisms of atrial fibrillation: impact on response to treatment (2013) (78)
Characterising the loss-of-function impact of 5’ untranslated region variants in 15,708 individuals (2019) (78)
Azithromycin Causes a Novel Proarrhythmic Syndrome (2017) (78)
Facilitating pharmacogenetic studies using electronic health records and natural-language processing: a case study of warfarin (2011) (78)
Drug-induced arrhythmia: pharmacogenomic prescribing? (2013) (77)
Pharmacology, electrophysiology, and pharmacokinetics of mexiletine. (1984) (77)
Genetic Risk Prediction of Atrial Fibrillation (2017) (77)
Exaggerated QT prolongation after cardioversion of atrial fibrillation. (1999) (77)
A common β1-adrenergic receptor polymorphism predicts favorable response to rate-control therapy in atrial fibrillation. (2012) (76)
A Structural Requirement for Processing the Cardiac K+ Channel KCNQ1* (2004) (76)
Clinical and Genetic Determinants of Warfarin Pharmacokinetics and Pharmacodynamics during Treatment Initiation (2011) (75)
K+ currents and K+ channel mRNA in cultured atrial cardiac myocytes (AT-1 cells). (1994) (75)
Genetic susceptibility to acquired long QT syndrome: pharmacologic challenge in first-degree relatives. (2005) (74)
Novel KCNA5 mutation implicates tyrosine kinase signaling in human atrial fibrillation. (2010) (74)
Divergent expression of delayed rectifier K(+) channel subunits during mouse heart development. (2001) (74)
Electrophysiologic Substrate in Congenital Long QT Syndrome: Noninvasive Mapping With Electrocardiographic Imaging (ECGI) (2014) (73)
The Autonomic Nervous System and Sudden Cardiac Death (2004) (73)
Development of the Cardiac Conduction System as Delineated by minK‐lacZ (2003) (73)
A practical approach to torsade de pointes (1997) (72)
Attitudes of Clinicians Following Large-Scale Pharmacogenomics Implementation (2015) (72)
Encainide and its metabolites. Comparative effects in man on ventricular arrhythmia and electrocardiographic intervals. (1984) (72)
Exome sequencing implicates an increased burden of rare potassium channel variants in the risk of drug-induced long QT interval syndrome. (2014) (71)
eMERGEing progress in genomics—the first seven years (2014) (71)
Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. (1989) (70)
Genomic medicine for undiagnosed diseases (2019) (69)
The effect of LRRK2 loss-of-function variants in humans (2020) (69)
Clinical pharmacology of propafenone: pharmacokinetics, metabolism and concentration-response relations. (1984) (68)
A sequence variant in ZFHX 3 on 16 q 22 associates with atrial fibrillation and ischemic stroke (2009) (68)
Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries (2017) (68)
Author Correction: Inherited causes of clonal haematopoiesis in 97,691 whole genomes (2021) (68)
Novel Rare Variants in Congenital Cardiac Arrhythmia Genes are Frequent in Drug-induced Torsades de Pointes (2012) (67)
Quinidine reduces clearance of (+)‐propranolol more than (−)‐propranolol through marked reduction in 4‐hydroxylation (1990) (67)
Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome (2018) (65)
Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment (2020) (65)
Cloning and initial characterization of the human cardiac sodium channel (SCN5A) promoter. (2004) (65)
A saturated map of common genetic variants associated with human height (2022) (65)
Four Susceptibility Loci for Gallstone Disease Identified in a Meta-analysis of Genome-Wide Association Studies. (2016) (65)
Evaluating electronic health record data sources and algorithmic approaches to identify hypertensive individuals (2017) (64)
Knowledge-Driven Multi-Locus Analysis Reveals Gene-Gene Interactions Influencing HDL Cholesterol Level in Two Independent EMR-Linked Biobanks (2011) (64)
Pharmacological Properties and Functional Role of Kslow Current in Mouse Pancreatic β-Cells (2005) (63)
SCN10A/Nav1.8 modulation of peak and late sodium currents in patients with early onset atrial fibrillation. (2014) (63)
Prolonged signal-averaged P-wave duration as an intermediate phenotype for familial atrial fibrillation. (2008) (63)
Genetic susceptibility for COVID-19–associated sudden cardiac death in African Americans (2020) (63)
High-throughput reclassification of SCN5A variants (2019) (63)
Plasminogen Activator Inhibitor-1 as a Predictor of Postoperative Atrial Fibrillation After Cardiopulmonary Bypass (2007) (63)
Classification and Reporting of Potentially Proarrhythmic Common Genetic Variation in Long QT Syndrome Genetic Testing (2018) (62)
Pharmacokinetics of amiodarone: implications for drug therapy. (1993) (62)
PR interval genome-wide association meta-analysis identifies 50 loci associated with atrial and atrioventricular electrical activity (2018) (61)
Co‐inheritance of the polymorphic metabolism of encainide and debrisoquin (1986) (61)
Phenome-wide association studies demonstrating pleiotropy of genetic variants within FTO with and without adjustment for body mass index (2014) (60)
Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation. (2001) (60)
A plethora of mechanisms in the HERG-related long QT syndrome. Genetics meets electrophysiology. (1999) (60)
Assessing the contribution of rare variants to complex trait heritability from whole-genome sequence data (2022) (60)
A Connexin40 Mutation Associated With a Malignant Variant of Progressive Familial Heart Block Type I (2012) (59)
Effect of low dose quinidine on encainide pharmacokinetics and pharmacodynamics. Influence of genetic polymorphism. (1989) (59)
LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins (2018) (58)
Harmonizing Clinical Sequencing and Interpretation for the eMERGE III Network. (2019) (58)
A Missense Variant in PLEC Increases Risk of Atrial Fibrillation. (2017) (57)
Whole Exome Sequencing Identifies a Causal RBM20 Mutation in a Large Pedigree With Familial Dilated Cardiomyopathy (2013) (57)
Relation of morbid obesity and female gender to risk of procedural complications in patients undergoing atrial fibrillation ablation. (2013) (57)
Drug therapy for atrial fibrillation: where do we go from here? (2005) (57)
Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes. (2019) (57)
Mechanism of block of a human cardiac potassium channel by terfenadine racemate and enantiomers (1995) (57)
Modulators of normal electrocardiographic intervals identified in a large electronic medical record. (2011) (57)
Size matters: How population size influences genotype-phenotype association studies in anonymized data (2014) (56)
Ibutilide and the treatment of atrial arrhythmias. A new drug--almost unheralded--is now available to US physicians. (1996) (55)
Genetic Variants in Transcription Factors Are Associated With the Pharmacokinetics and Pharmacodynamics of Metformin (2014) (55)
Drug therapy. Tocainide. (1986) (55)
Transethnic Genome-Wide Association Study Provides Insights in the Genetic Architecture and Heritability of Long QT Syndrome (2020) (55)
Genotype and risk of major bleeding during warfarin treatment. (2014) (54)
Comparison of HLA allelic imputation programs (2017) (54)
Enhancing Literacy in Cardiovascular Genetics: A Scientific Statement From the American Heart Association (2016) (54)
Analysis for Genetic Modifiers of Disease Severity in Patients With Long-QT Syndrome Type 2 (2015) (53)
Genome Wide Analysis of Drug-Induced Torsades de Pointes: Lack of Common Variants with Large Effect Sizes (2013) (53)
Hypogonadism as a Reversible Cause of Torsades de Pointes in Men. (2018) (53)
IKr drug response is modulated by KCR1 in transfected cardiac and noncardiac cell lines (2003) (52)
In vivo identification of genes that modify ether-a-go-go-related gene activity in Caenorhabditis elegans may also affect human cardiac arrhythmia. (2004) (52)
New Mechanism Contributing to Drug-Induced Arrhythmia: Rescue of a Misprocessed LQT3 Mutant (2005) (52)
Magnesium treatment of ventricular arrhythmias. (1989) (52)
Potent electrophysiologic effects of the major metabolites of propafenone in canine Purkinje fibers. (1988) (51)
The cardiac ion channels: relevance to management of arrhythmias. (1996) (51)
Transcription factor ETV1 is essential for rapid conduction in the heart. (2016) (50)
Ionic mechanisms for prolongation of refractoriness and their proarrhythmic and antiarrhythmic correlates. (1996) (50)
Leveraging the electronic health record to implement genomic medicine (2012) (50)
Differential activation of natriuretic peptide receptors modulates cardiomyocyte proliferation during development (2014) (50)
Assessment of the Relationship Between Genetic Determinants of Thyroid Function and Atrial Fibrillation: A Mendelian Randomization Study (2019) (50)
Antiarrhythmic drugs: from mechanisms to clinical practice (2000) (50)
Effects of congestive heart failure on the pharmacokinetics and pharmacodynamics of antiarrhythmic agents. (1986) (49)
Antiarrhythmic activity of the O-demethyl metabolite of encainide. (1982) (49)
Opportunities, resources, and techniques for implementing genomics in clinical care (2019) (49)
A genome-wide association study of heparin-induced thrombocyto - penia using an electronic medical record (2014) (48)
A clinical prediction model to estimate risk for 30-day adverse events in emergency department patients with symptomatic atrial fibrillation. (2009) (48)
Risperidone Prolongs Cardiac Repolarization by Blocking the Rapid Component of the Delayed Rectifier Potassium Current (2003) (48)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes (2019) (48)
Recent Advances in Understanding the Molecular Mechanisms of the Long QT Syndrome (1995) (47)
Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes (1988) (47)
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin‐Associated Musculoskeletal Symptoms (2022) (47)
Pharmacogenomic Polygenic Response Score Predicts Ischemic Events and Cardiovascular Mortality in Clopidogrel-Treated Patients. (2019) (47)
Persistent atrial fibrillation is associated with reduced risk of torsades de pointes in patients with drug-induced long QT syndrome. (2008) (47)
Stereoselective genetically-determined interaction between chronic flecainide and quinidine in patients with arrhythmias. (1992) (46)
High Density GWAS for LDL Cholesterol in African Americans Using Electronic Medical Records Reveals a Strong Protective Variant in APOE (2012) (46)
Tocainide therapy for refractory ventricular arrhythmias. (1980) (46)
CTNNA3 and SEMA3D: Promising loci for asthma exacerbation identified through multiple genome-wide association studies. (2015) (46)
Evaluation of a Prediction Model for the Development of Atrial Fibrillation in a Repository of Electronic Medical Records. (2016) (46)
Electrophysiologic actions of high plasma concentrations of propranolol in human subjects. (1983) (46)
Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update (2022) (46)
Nkx 2-5 mutation causes anatomic hypoplasia of the cardiac conduction system (45)
PCSK 9 genetic variants and risk of type 2 diabetes : a mendelian randomisation study (2020) (45)
Functional modeling in zebrafish demonstrates that the atrial-fibrillation-associated gene GREM2 regulates cardiac laterality, cardiomyocyte differentiation and atrial rhythm (2012) (45)
Race-specific impact of atrial fibrillation risk factors in blacks and whites in the southern community cohort study. (2012) (45)
Keep the QT interval: it is a reliable predictor of ventricular arrhythmias. (2008) (45)
Molecular cloning and analysis of zebrafish voltage-gated sodium channel beta subunit genes: implications for the evolution of electrical signaling in vertebrates (2007) (45)
Phosphorylation of the IKs Channel Complex Inhibits Drug Block: Novel Mechanism Underlying Variable Antiarrhythmic Drug Actions (2003) (45)
Characterization of Genome-Wide Association-Identified Variants for Atrial Fibrillation in African Americans (2012) (44)
Clinical, Genetic, and Biophysical Characterization of a Homozygous HERG Mutation Causing Severe Neonatal Long QT Syndrome (2003) (44)
Dietary salt increases first‐pass elimination of oral quinidine (1997) (44)
Antiarrhythmic activity, electrocardiographic effects and pharmacokinetics of the encainide metabolites O-desmethyl encainide and 3-methoxy-O-desmethyl encainide in man. (1988) (44)
Epinephrine-induced changes in serum potassium and cardiac repolarization and effects of pretreatment with propranolol and diltiazem. (1996) (44)
Acute electrophysiologic effects of sodium administration in dogs treated with O-desmethyl encainide. (1989) (44)
A genome-wide association study identifies variants in KCNIP4 associated with ACE inhibitor-induced cough (2015) (43)
Suppression of Bidirectional Ventricular Tachycardia and Unmasking of Prolonged QT interval with Verapamil in Andersen's Syndrome (2004) (43)
Effects of Procainamide and Lidocaine on Defibrillation Energy Requirements in Patients Receiving Implantable Cardioverter Defibrillator Devices (1994) (43)
Genome-wide association and pathway analysis of left ventricular function after anthracycline exposure in adults (2017) (43)
Frequency- and orientation-dependent effects of mexiletine and quinidine on conduction in the intact dog heart. (1987) (42)
Abnormalities of the QT interval in primary disorders of autonomic failure. (1998) (42)
Practical considerations in genomic decision support: The eMERGE experience (2015) (42)
Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation (2018) (42)
Polymorphism Screening in the Cardiac K+ Channel Gene KCNA5 (2005) (42)
Genetic Variants That Confer Resistance to Malaria Are Associated with Red Blood Cell Traits in African-Americans: An Electronic Medical Record-based Genome-Wide Association Study (2013) (42)
Arrhythmogenic right ventricular cardiomyopathy due to a novel plakophilin 2 mutation: wide spectrum of disease in mutation carriers within a family. (2006) (42)
Penetrance of Hemochromatosis in HFE Genotypes Resulting in p.Cys282Tyr and p.[Cys282Tyr];[His63Asp] in the eMERGE Network (2015) (42)
Human genomics and its impact on arrhythmias. (2004) (41)
Refining repolarization reserve. (2011) (41)
The pause that refreshes, or does it? Mechanisms in torsades de pointes (2000) (41)
Electrophysiologic actions of O-demethyl encainide: an active metabolite. (1983) (41)
Predicting the long-QT genotype from clinical data: from sense to science. (2000) (40)
Human MRP3 transporter: identification of the 5'-flanking region, genomic organization and alternative splice variants. (1999) (40)
Apolipoprotein L1 Variants and Blood Pressure Traits in African Americans. (2017) (40)
Pharmacological properties and functional role of Kslow current in mouse pancreatic beta-cells: SK channels contribute to Kslow tail current and modulate insulin secretion. (2005) (40)
Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls (2020) (39)
Biophysical Properties of 9 KCNQ1 Mutations Associated With Long-QT Syndrome (2009) (39)
Factors affecting the degree of QT prolongation with drug challenge in a large cohort of normal volunteers. (2011) (38)
Multi-ancestry GWAS of the electrocardiographic PR interval identifies 202 loci underlying cardiac conduction (2019) (38)
Genetic and Clinical Risk Prediction Model for Postoperative Atrial Fibrillation (2015) (38)
Increased late sodium current contributes to long QT-related arrhythmia susceptibility in female mice. (2012) (37)
A Randomized, Double‐Blind, Placebo‐Controlled, Dose‐Ranging Study of Dofetilide in Patients with Inducible Sustained Ventricular Tachyarrhythmias (1995) (37)
Increased long QT and torsade de pointes reporting on tamoxifen compared with aromatase inhibitors (2018) (36)
Systems biology and cardiac arrhythmias (2012) (36)
The Influence of Big (Clinical) Data and Genomics on Precision Medicine and Drug Development (2018) (36)
The search for novel antiarrhythmic strategies (1998) (36)
Polymorphisms in the cardiac sodium channel promoter displaying variant in vitro expression activity (2008) (36)
Whole-exome sequencing in familial atrial fibrillation. (2014) (35)
Consortium ( CPIC ) guidelines for cytochrome P 450-2 C 19 ( CYP 2 C 19 ) genotype and clopidogrel therapy (2011) (35)
Genetic Variants Associated with Serum Thyroid Stimulating Hormone (TSH) Levels in European Americans and African Americans from the eMERGE Network (2014) (35)
Polymorphisms in Beta‐Adrenergic Receptor Genes in the Acquired Long QT Syndrome (2002) (35)
The E 1784 K mutation in SCN 5 A is associated with mixed clinical phenotype of type 3 long QT syndrome (2008) (35)
Building evidence and measuring clinical outcomes for genomic medicine (2019) (34)
Modulation of cardiac Na+ current phenotype by beta1-subunit expression. (1998) (34)
Quinidine‐enhanced β‐blockade during treatment with propafenone in extensive metabolizer human subjects (1994) (34)
The All of Us Research Program: Data quality, utility, and diversity (2020) (34)
Genome‐wide and Phenome‐wide Approaches to Understand Variable Drug Actions in Electronic Health Records (2017) (34)
Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease. (2016) (34)
CHLAMYDIA INFECTION (2001) (34)
Comparative in vitro electrophysiology of quinidine, its major metabolites and dihydroquinidine. (1987) (34)
The Organic Cation Transporter, OCTN1, Expressed in the Human Heart, Potentiates Antagonism of the HERG Potassium Channel (2009) (33)
Responding to the clopidogrel warning by the US food and drug administration: real life is complicated. (2010) (33)
Global parameter optimization for cardiac potassium channel gating models. (1990) (33)
Differential effects of O-demethyl encainide on induced and spontaneous arrhythmias in the conscious dog. (1984) (33)
Accelerating Precision Drug Development and Drug Repurposing by Leveraging Human Genetics. (2017) (33)
SCN5A (NaV1.5) Variant Functional Perturbation and Clinical Presentation: Variants of a Certain Significance (2018) (33)
Modulation by dietary salt of verapamil disposition in humans. (1998) (33)
Novel KCNQ1 mutations associated with recessive and dominant congenital long QT Syndromes: Evidence for variable hearing phenotype associated with R518X (2000) (33)
Phenome‐wide association studies: a new method for functional genomics in humans (2017) (32)
Spectrum of antiarrhythmic response to encainide. (1985) (32)
Generalization of Variants Identified by Genome‐Wide Association Studies for Electrocardiographic Traits in African Americans (2013) (32)
Early-Onset Atrial Fibrillation and the Prevalence of Rare Variants in Cardiomyopathy and Arrhythmia Genes (2021) (32)
Suppression of ventricular arrhythmias in man by d-propranolol independent of beta-adrenergic receptor blockade. (1990) (32)
Association Between Early Postoperative Acetaminophen Exposure and Acute Kidney Injury in Pediatric Patients Undergoing Cardiac Surgery (2018) (32)
CMTR1 is associated with increased asthma exacerbations in patients taking inhaled corticosteroids (2015) (32)
Cardiac-enriched LIM domain protein fhl2 is required to generate I(Ks) in a heterologous system. (2002) (31)
Single inward rectifier potassium channels in guinea pig ventricular myocytes. Effects of quinidine. (1991) (31)
Symptomatic burden as an endpoint to evaluate interventions in patients with atrial fibrillation. (2005) (31)
QT prolongation and arrhythmia suppression. (1985) (31)
Flecainide dose-response relations in stable ventricular arrhythmias. (1984) (31)
A current understanding of drug-induced QT prolongation and its implications for anticancer therapy. (2019) (30)
Disposition kinetics of encainide and metabolites. (1986) (30)
ACE I/D polymorphism associated with abnormal atrial and atrioventricular conduction in lone atrial fibrillation and structural heart disease: implications for electrical remodeling. (2009) (30)
A multi-stage genome-wide association study of uterine fibroids in African Americans (2017) (30)
SCN5A Mutation Type and a Genetic Risk Score Associate Variably With Brugada Syndrome Phenotype in SCN5A Families (2020) (30)
International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug‐induced torsades de pointes (2008) (29)
Atrial fibrillation genetic risk differentiates cardioembolic stroke from other stroke subtypes (2018) (29)
Cardiovascular pharmacogenomics: current status and future directions (2015) (29)
Calmodulin kinase II activity is required for normal atrioventricular nodal conduction. (2005) (28)
Proarrhythmia as a pharmacogenomic entity: a critical review and formulation of a unifying hypothesis. (2005) (28)
Genome-wide study of resistant hypertension identified from electronic health records (2017) (28)
Frequency-dependent interactions of mexiletine and quinidine on depolarization and repolarization in canine Purkinje fibers. (1987) (28)
CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease. (2016) (28)
Probing the Virtual Proteome to Identify Novel Disease Biomarkers (2018) (28)
The International Serious Adverse Events Consortium (iSAEC) phenotype standardization project for drug-induced torsades de pointes. (2013) (27)
An analytical approach to characterize morbidity profile dissimilarity between distinct cohorts using electronic medical records (2010) (27)
Drug‐Induced J Point Elevation (1999) (27)
Electrophysiologic effects of intravenous and oral sotalol for sustained ventricular tachycardia secondary to coronary artery disease. (1988) (27)
A case study evaluating the portability of an executable computable phenotype algorithm across multiple institutions and electronic health record environments (2018) (27)
Left atrial hypertension after repeated catheter ablations for atrial fibrillation. (2011) (27)
Preprescription genotyping: not yet ready for prime time, but getting there. (2001) (26)
Pharmacogenetics of antiarrhythmic therapy (2006) (26)
Clinical and Genetic Factors Associated With Cutaneous Squamous Cell Carcinoma in Kidney and Heart Transplant Recipients (2015) (26)
Drug therapy. Encainide. (1988) (26)
Genetically determined steady-state interaction between encainide and quinidine in patients with arrhythmias. (1990) (26)
Accelerating Biomarker Discovery Through Electronic Health Records, Automated Biobanking, and Proteomics. (2019) (26)
Deep Mutational Scan of an SCN5A Voltage Sensor (2020) (26)
P1-84: Metabolic syndrome and risk of development of atrial fibrillation (2006) (26)
Human cardiac potassium channel DNA polymorphism modulates access to drug-binding site and causes drug resistance. (2005) (26)
High-throughput discovery of trafficking-deficient variants in the cardiac potassium channel KV11.1. (2020) (25)
Association of Thyroid Function Genetic Predictors With Atrial Fibrillation: A Phenome-Wide Association Study and Inverse-Variance Weighted Average Meta-analysis (2019) (25)
A mechanism of D-(+)-sotalol effects on heart rate not related to beta-adrenoceptor antagonism. (1990) (25)
From genes to channels: normal mechanisms. (1999) (25)
Defining Phenotypes from Clinical Data to Drive Genomic Research. (2018) (25)
New approaches to antiarrhythmic therapy; emerging therapeutic applications of the cell biology of cardiac arrhythmias. (2001) (25)
Frequency of genomic incidental findings among 21,915 eMERGE network participants (2020) (25)
Phenome-wide association analysis of LDL-cholesterol lowering genetic variants in PCSK9 (2018) (25)
Cardiovascular Effects of Noncardiovascular Drugs (2009) (25)
SCN5A Variation Is Associated With Electrocardiographic Traits in the Jackson Heart Study (2011) (25)
Encainide disposition in patients with chronic cirrhosis (1986) (25)
Class I antiarrhythmic agents: quinidine, procainamide and N-acetylprocainamide, disopyramide. (1983) (24)
Development of a System for Postmarketing Population Pharmacokinetic and Pharmacodynamic Studies Using Real‐World Data From Electronic Health Records (2020) (24)
Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records. (2013) (24)
Encainide disposition in patients with renal failure (1986) (24)
Flecainide enantiomers: Disposition in human subjects and electrophysiologic actions in vitro (1989) (24)
Future of antiarrhythmic drugs (2006) (24)
Recombinase‐mediated cassette exchange to rapidly and efficiently generate mice with human cardiac sodium channels (2006) (24)
Pharmacologic causes of arrhythmogenic actions of antiarrhythmic drugs. (1987) (24)
Improving the phenotype risk score as a scalable approach to identifying patients with Mendelian disease (2019) (24)
Pharmacogenomics: will the promise be fulfilled? (2011) (24)
Calmodulin Inhibitor W7 Unmasks a Novel Electrocardiographic Parameter That Predicts Initiation of Torsade de Pointes (2002) (24)
Identification of unique venous thromboembolism-susceptibility variants in African-Americans (2017) (24)
Comparison of the effects of placebo and encainide on programmed electrical stimulation and ventricular arrhythmia frequency. (1982) (24)
Understanding the use of observational and randomized data in cardiovascular medicine. (2020) (23)
Enabling Genomic-Phenomic Association Discovery without Sacrificing Anonymity (2013) (23)
A new method for constant plasma drug concentrations: application to lidocaine. (1984) (23)
Inhibition of the α-Subunit of Phosphoinositide 3-Kinase in Heart Increases Late Sodium Current and Is Arrhythmogenic (2018) (23)
Risk Factor Interactions and Genetic Effects Associated with Post-Operative Atrial Fibrillation (2005) (23)
Inherited Causes of Clonal Hematopoiesis of Indeterminate Potential in TOPMed Whole Genomes (2019) (23)
Informatic and Functional Approaches to Identifying a Regulatory Region for the Cardiac Sodium Channel (2011) (23)
Contrasting Nav1.8 Activity in Scn10a −/− Ventricular Myocytes and the Intact Heart (2016) (22)
Genomewide Association Study of Platelet Reactivity and Cardiovascular Response in Patients Treated With Clopidogrel: A Study by the International Clopidogrel Pharmacogenomics Consortium (2020) (22)
Pharmacology of the class III antiarrhythmic agent sematilide in patients with arrhythmias. (1992) (22)
Genome‐wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points—Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC) (2017) (22)
Genome-wide Study Identifies Association between HLA-B∗55:01 and Self-Reported Penicillin Allergy (2020) (22)
Suppression of Longitudinal Versus Transverse Conduction by Sodium Channel Block: Effects of Sodium Bolus (1992) (22)
Genome-Wide Association Study of Serum Creatinine Levels during Vancomycin Therapy (2015) (22)
Variants in the SCN5A Promoter Associated With Various Arrhythmia Phenotypes (2016) (22)
Inherited causes of clonal haematopoiesis in 97,691 whole genomes (2020) (21)
Effect of Fluosol-DA on infarct morphology and vulnerability to ventricular arrhythmia. (1986) (21)
Data re-identification: societal safeguards. (2013) (21)
Cardiovascular Pharmacogenomics: Current Status and Future Directions—Report of a National Heart, Lung, and Blood Institute Working Group (2012) (21)
Opportunities and Challenges in Cardiovascular Pharmacogenomics: From Discovery to Implementation. (2018) (21)
An International Multi-Center Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. (2020) (21)
Common SCN10A variants modulate PR interval and heart rate response during atrial fibrillation. (2014) (21)
Applied pharmacogenomics in cardiovascular medicine. (2014) (21)
A conceptual model for translating omic data into clinical action (2015) (21)
Using systems approaches to address challenges for clinical implementation of pharmacogenomics (2014) (20)
Inhibition of cardiac potassium currents by the vesnarinone analog OPC-18790: comparison with quinidine and dofetilide. (1997) (20)
KCNE1 induces fenestration in the Kv7.1/KCNE1 channel complex that allows for highly specific pharmacological targeting (2016) (20)
Relationship between very low low-density lipoprotein cholesterol concentrations not due to statin therapy and risk of type 2 diabetes: A US-based cross-sectional observational study using electronic health records (2018) (20)
Deciphering Signaling Pathway Networks to Understand the Molecular Mechanisms of Metformin Action (2015) (19)
Usefulness of sotalol for life-threatening ventricular arrhythmias. (1993) (19)
A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR (2019) (19)
Mechanistic Phenotypes: An Aggregative Phenotyping Strategy to Identify Disease Mechanisms Using GWAS Data (2013) (19)
The Future of Cardiovascular Therapeutics. (2016) (19)
Anticancer drug-induced life-threatening ventricular arrhythmias: a World Health Organization pharmacovigilance study. (2021) (19)
The AFFORD clinical decision aid to identify emergency department patients with atrial fibrillation at low risk for 30-day adverse events. (2015) (19)
Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility (2022) (19)
A polymorphism in HLA-G modifies statin benefit in asthma (2014) (19)
A Trans-Ethnic Genome-Wide Association Study of Uterine Fibroids (2019) (19)
CYP2C19 Phenotype and Risk of Proton Pump Inhibitor–Associated Infections (2019) (19)
Pharmacology and Toxicology of Nav1.5-Class 1 Antiarrhythmic Drugs (2014) (19)
Genetic Susceptibility for Atrial Fibrillation in Patients Undergoing Atrial Fibrillation Ablation (2020) (19)
Pharmacokinetic and Pharmacodynamic Interaction of N‐Acetyl Procainamide and Procainamide in Humans (1989) (19)
New approaches to antiarrhythmic therapy: emerging therapeutic applications of the cell biology of cardiac arrhythmias(1). (2001) (18)
Heart failure and atrial tachyarrhythmia on abiraterone: A pharmacovigilance study. (2019) (18)
Genome sequencing unveils a regulatory landscape of platelet reactivity (2019) (18)
Merging Electronic Health Record Data and Genomics for Cardiovascular Research: A Science Advisory From the American Heart Association (2016) (18)
Candidate gene approach to identifying rare genetic variants associated with lone atrial fibrillation. (2014) (18)
A Rate‐Independent Method of Assessing QT‐RR Slope Following Conversion of Atrial Fibrillation (2007) (18)
A Genotype-Dependent Intermediate ECG Phenotype in Patients With Persistent Lone Atrial Fibrillation: Genotype ECG-Phenotype Correlation in Atrial Fibrillation (2009) (18)
Autonomic Tone Attenuates Drug‐Induced QT Prolongation (2007) (18)
Importance of metabolites in antiarrhythmic therapy. (1983) (18)
Brugada‐Type ECG Pattern and Extreme QRS Complex Widening with Propafenone Overdose (2006) (18)
An underrecognized challenge in evaluating postmarketing drug safety. (2005) (18)
Mexiletine and tocainide: A comparison of antiarrhythmic efficacy, adverse effects, and predictive value of lidocaine testing (1989) (18)
Common variants at SCN5A-SCN10A and HEY2 are associated with Brugada syndrome, a rare disease with high risk of sudden cardiac death (2013) (17)
GRIK5 Genetically Regulated Expression Associated with Eye and Vascular Phenomes: Discovery through Iteration among Biobanks, Electronic Health Records, and Zebrafish. (2019) (17)
Cardiovascular pharmacogenomics. (2011) (17)
Mechanisms underlying variability in response to drug therapy: implications for amiodarone use. (1999) (17)
Antiarrhythmic drugs: past, present, and future. (2004) (17)
The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval process. (2005) (17)
Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of indeterminate potential (2022) (17)
On the relationship among QT interval, atrial fibrillation, and torsade de pointes. (2007) (17)
Abstract 14587: Proarrhythmic Effects of Ibrutinib, a Clinically Approved Inhibitor of Bruton’S Tyrosine Kinase (BTK) Used in Cancer Therapy (2015) (17)
Deep learning analysis of electrocardiogram for risk prediction of drug-induced arrhythmias and diagnosis of long QT syndrome. (2021) (16)
Response to the editorial “COVID-19 in patients with cardiovascular diseases” (2020) (16)
PheMap: a multi-resource knowledge base for high-throughput phenotyping within electronic health records (2020) (16)
Rate‐Independent QT Shortening During Exercise in Healthy Subjects: Terminal Repolarization Does Not Shorten with Exercise (2008) (16)
A retrospective approach to evaluating potential adverse outcomes associated with delay of procedures for cardiovascular and cancer-related diagnoses in the context of COVID-19 (2020) (16)
Genome‐Wide Association and Functional Studies Reveal Novel Pharmacological Mechanisms for Allopurinol (2019) (16)
Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics? (2013) (16)
Genetic determinants of response to cardiovascular drugs (2012) (16)
Using Human ‘Experiments of Nature’ to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors (2018) (16)
Calcium channel blockers as drug repurposing candidates for gestational diabetes: Mining large scale genomic and electronic health records data to repurpose medications (2018) (16)
Protein structure aids predicting functional perturbation of missense variants in SCN5A and KCNQ1 (2019) (16)
Visual Integration of Results from a Large Dna Biobank (Biovu) Using Synthesis-View (2011) (16)
Variation in the 4 q 25 Chromosomal Locus Predicts Atrial Fibrillation After Coronary Artery Bypass Graft Surgery (2009) (16)
The problem, challenge and opportunity of genetic heterogeneity in monogenic diseases predisposing to sudden death. (2002) (16)
A surprising new arrhythmia mechanism in heart failure. (2003) (16)
Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network (2019) (15)
Modeling drug exposure data in electronic medical records: an application to warfarin. (2011) (15)
Antiarrhythmic Drugs: (2003) (15)
A prognostic model based on readily available clinical data enriched a pre-emptive pharmacogenetic testing program. (2016) (15)
QT variability during initial exposure to sotalol: experience based on a large electronic medical record. (2013) (15)
Genetic determinants of telomere length from 109,122 ancestrally diverse whole-genome sequences in TOPMed (2022) (15)
Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium (2017) (15)
Sympathetic Activation Enhances QT Prolongation by Quinidine (2001) (15)
Proliferation of embryonic cardiomyocytes in zebrafish requires the sodium channel scn5Lab (2013) (15)
Regulation of sodium current development in cultured atrial tumor myocytes (AT-1 cells). (1996) (15)
Pharmacogenomics and Cardiovascular Disease (2013) (14)
Identification of Central Regulators of Calcium Signaling and ECM–Receptor Interaction Genetically Associated With the Progression and Recurrence of Atrial Fibrillation (2018) (14)
Personalized medicine and the genotype–phenotype dilemma (2011) (14)
An International Multicenter Evaluation of Type 5 Long QT Syndrome (2020) (14)
Effects of Drug Metabolism, Metabolites, and Stereoselectivity on Antiarrhythmic Drug Action (1990) (14)
A common variant on chromosome 4q25 is associated with prolonged PR interval in subjects with and without atrial fibrillation. (2014) (14)
Influence of Human Leukocyte Antigen (HLA) Alleles and Killer Cell Immunoglobulin‐Like Receptors (KIR) Types on Heparin‐Induced Thrombocytopenia (HIT) (2017) (14)
Admixture Mapping and Subsequent Fine-Mapping Suggests a Biologically Relevant and Novel Association on Chromosome 11 for Type 2 Diabetes in African Americans (2014) (14)
Coinheritance of long QT syndrome and Kearns-Sayre syndrome. (2007) (14)
Clopidogrel Pharmacogenetics - Why the Wait? (2019) (14)
Lack of Triggered Automaticity Despite Repolarization Abnormalities due to Bepridil and Lidoflazine (1990) (14)
Identifying genetically driven clinical phenotypes using linear mixed models (2016) (13)
Genetic Polymorphisms, Drugs, and Proarrhythmia (2003) (13)
CYP2D6 genotype and adverse events to risperidone in children and adolescents (2019) (13)
Phenotype-Driven Plasma Biobanking Strategies and Methods (2015) (13)
Utilization of an EMR-Biorepository to Identify the Genetic Predictors of Calcineurin-Inhibitor Toxicity in Heart Transplant Recipients (2013) (13)
Drug-induced prolongation of the QT interval [2] (multiple letters) (2004) (13)
Electropharmacologic synergism with mexiletine and quinidine. (1986) (13)
Genetically determined stereoselective excretion of encainide in humans and electrophysiologic effects of its enantiomers in canine cardiac Purkinje fibers (1991) (13)
Pharmacologic reversal of hypotensive effect complicating antiarrhythmic therapy with bretylium (1982) (13)
Clinical Pharmacokinetics of Encainide (1988) (13)
Genetic variation in the β1-adrenergic receptor is associated with the risk of atrial fibrillation after cardiac surgery. (2014) (12)
Genetic variation in the rhythmonome: ethnic variation and haplotype structure in candidate genes for arrhythmias. (2009) (12)
Stem cell-derived cardiomyocytes as a tool for studying proarrhythmia: a better canary in the coal mine? (2013) (12)
Torsades de pointes with high-dose loperamide. (2017) (12)
Evaluating statistical approaches to leverage large clinical datasets for uncovering therapeutic and adverse medication effects (2018) (12)
Influence of the G2677T/C3435T haplotype of MDR1 on P-glycoprotein trafficking and ibutilide-induced block of HERG (2009) (12)
Reply to Goldman (1991) (12)
Electrophysiologic and hemodynamic effects of chronic oral therapy with the α2‐agonists clonidine and tiamenidine in hypertensive volunteers (1988) (12)
Electrophysiology of O‐Demethyl Encainide in a Canine Model of Sustained Ventricular Tachycardia (1984) (12)
A new role for calmodulin in ion channel biology. (2006) (12)
Pharmacogenetics of Potassium Channel Blockers. (2016) (11)
Phenome-Wide Association Studies. (2022) (11)
A study paradigm integrating prospective epidemiologic cohorts and electronic health records to identify disease biomarkers (2018) (11)
A genome-wide association study to identify genomic modulators of rate control therapy in patients with atrial fibrillation. (2014) (11)
Novel Brugada SCN5A mutation causing sudden death in children. (2005) (11)
An Allosteric Mechanism for Drug Block of the Human Cardiac Potassium Channel KCNQ1 (2013) (11)
Creation and Validation of an EMR-based Algorithm for Identifying Major Adverse Cardiac Events while on Statins (2014) (11)
Molecular basis for the antigenicity of lidocaine analogs: tocainide and mexiletine. (1984) (11)
Association of Pathogenic Variants in Hereditary Cancer Genes With Multiple Diseases. (2022) (11)
Clinical features of arrhythmia aggravation by antiarrhythmic drugs and their implications for basic mechanisms (1990) (11)
Cardiovascular and Renal Advisory Panel of the US Food and Drug Administration Considers Four Drugs (1997) (11)
The molecular genetics of arrhythmias. (2005) (11)
KCNH2 pharmacogenomics summary. (2010) (11)
Magnetic resonance imaging in orbital diagnosis. (1988) (11)
Role of the electrocardiogram in determining electrophysiologic end points of drug therapy. (1988) (11)
Atrial fibrillation and flutter outcomes and risk determination (AFFORD): design and rationale. (2011) (10)
Sudden Cardiac Death Prediction and Prevention (2010) (10)
Effect of Hypercapnic Acidemia on Anisotropic Propagation in the Canine Ventricle (1994) (10)
Integrating gene expression and clinical data to identify drug repurposing candidates for hyperlipidemia and hypertension (2022) (10)
Principles in Pharmacogenetics (2001) (10)
Examining Rare and Low-Frequency Genetic Variants Previously Associated With Lone or Familial Forms of Atrial Fibrillation in an Electronic Medical Record System: A Cautionary Note (2014) (10)
The development and testing of intravenous dosing regimens: Application to flecainide for the suppression of ventricular arrhythmias (1988) (10)
Is there a need for new antiarrhythmic drugs? (1996) (10)
Indications for Different Modes of Surgical Therapy in Medically Refractory Ventricular Arrhythmias (1986) (10)
Bidirectional ventricular tachycardia and channelopathy. (2003) (10)
Pharmacogenetics to Predict Adverse Events Associated With Antidepressants (2020) (10)
Spectrum of cardiovascular toxicities of immune checkpoint inhibitors: A pharmacovigilance study (2018) (10)
Atropine-induced sinus tachycardia protects against exercise-induced ventricular arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. (2020) (10)
Potential Applications of Free Drug Level Monitoring in Cardiovascular Therapy† (1984) (10)
Abstract 1971: Genome-wide Association Study Identifies Novel Genomic Regions Associated With Drug-induced Long Qt Syndrome (2009) (10)
Chapter 1 – Molecular and Cellular Basis of Cardiac Electrophysiology (2005) (9)
Genetic nondiscrimination legislation: a critical prerequisite for pharmacogenomics data sharing. (2007) (9)
Considerations for drug interactions on QTc interval in exploratory COVID-19 treatment (2020) (9)
Association Between a Common, Benign Genotype and Unnecessary Bone Marrow Biopsies Among African American Patients. (2021) (9)
Hypertension genetic risk score is associated with burden of coronary heart disease among patients referred for coronary angiography (2018) (9)
Atrial Fibrillation in KCNE 1-Null Mice (2005) (9)
Antiarrhythmic efficacy, clinical electrophysiology, and pharmacokinetics of 3-methoxy-O-desmethyl encainide (MODE) in patients with inducible ventricular tachycardia or fibrillation. (1989) (9)
Selection of an antiarrhythmic drug for a sudden-death-prevention trial. (1982) (9)
Cardiovascular pharmacogenomics. (2003) (9)
Predictive Accuracy of a Polygenic Risk Score for Postoperative Atrial Fibrillation After Cardiac Surgery (2021) (9)
Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugs. (2014) (9)
Adverse Events Associated with Risperidone Use in Pediatric Patients: A Retrospective Biobank Study (2019) (9)
A Decision-Theoretic Approach to Panel-Based, Preemptive Genotyping (2019) (9)
How Will Genetics Inform the Clinical Care of Atrial Fibrillation? (2020) (9)
Investigating the Genetic Architecture of the PR Interval Using Clinical Phenotypes (2017) (9)
Population‐specific single‐nucleotide polymorphism confers increased risk of venous thromboembolism in African Americans (2016) (9)
FDA Panel report: January 1998. (1998) (9)
Tocainide plus quinidine for treatment of ventricular arrhythmias. (1988) (9)
Brugada syndrome: lots of questions, some answers. (2010) (9)
Evaluation of the F2R IVS-14A/T PAR1 polymorphism with subsequent cardiovascular events and bleeding in patients who have undergone percutaneous coronary intervention (2016) (9)
Modulation of effect of dietary salt on prehepatic first-pass metabolism: effects of beta-blockade and intravenous salt loading. (1999) (9)
Multiplex ligation-dependent probe amplification copy number variant analysis in patients with acquired long QT syndrome. (2015) (9)
Toward a molecular view of cardiac arrhythmogenesis. (1994) (8)
Pharmacokinetic Profile of Encainide (1989) (8)
Repetitive transcranial magnetic stimulation (TMS) for medication-resistant depression. (2009) (8)
A spotlight on electrophysiological remodeling and the molecular biology of ion channels. (1999) (8)
On the Potential of Preemptive Genotyping Towards Preventing Medication-Related Adverse Events: Results from the South Korean National Health Insurance Database (2016) (8)
Stereoselective determination of flecainide in human plasma by high-performance liquid chromatography with fluorescence detection. (1990) (8)
The 3D mutational constraint on amino acid sites in the human proteome (2022) (8)
Phenotyping coronavirus disease 2019 during a global health pandemic: Lessons learned from the characterization of an early cohort (2021) (8)
Pleiotropy in the Genetic Predisposition to Rheumatoid Arthritis: A Phenome‐Wide Association Study and Inverse Variance–Weighted Meta‐Analysis (2020) (8)
Association of step counts over time with the risk of chronic disease in the All of Us Research Program (2022) (8)
Strategies for Equitable Pharmacogenomic-Guided Warfarin Dosing Among European and African American Individuals in a Clinical Population (2017) (8)
Arrhythmia pharmacogenomics: methodological considerations. (2009) (8)
Modulation of drug block of the cardiac potassium channel KCNA5 by the drug transporters OCTN1 and MDR1 (2010) (7)
Shared Decision-Making in Cardiac Electrophysiology Procedures and Arrhythmia Management. (2021) (7)
An APOO Pseudogene on Chromosome 5q Is Associated With Low-Density Lipoprotein Cholesterol Levels (2018) (7)
The polygenic architecture of left ventricular mass mirrors the clinical epidemiology (2020) (7)
Genomic Medicine Year in Review: 2019. (2019) (7)
Molecular characterization and investigation of the role of genetic variation in phenotypic variability and response to treatment in a large pediatric Marfan syndrome cohort (2022) (7)
Abstract 16237: Striking Electrophysiologic Differences Between Cardiac Sodium Channel Isoforms SCN10A and SCN5A (2011) (7)
Acute kidney injury risk-based screening in pediatric inpatients: A pragmatic randomized trial (2019) (7)
Arrhythmia Variant Associations and Reclassifications in the eMERGE-III Sequencing Study (2021) (7)
SCN5A variant R222Q generated abnormal changes in cardiac sodium current and action potentials in murine myocytes and Purkinje cells. (2019) (7)
Bretylium: relations between plasma concentrations and pharmacologic actions in high-frequency ventricular arrhythmias. (1985) (7)
Probing the mechanisms underlying modulation of quinidine sensitivity to cardiac IKs block by protein kinase A‐mediated IKs phosphorylation (2009) (7)
Discovering patterns of pleiotropy in genome-wide association studies (2018) (7)
Defective ion channel function in the long QT syndrome: multiple unexpected mechanisms. (2001) (7)
Control of ventricular preexcitation and associated arrhythmias by encainide. (1981) (7)
Dantrolene: from better bacon to a treatment for ventricular fibrillation. (2014) (7)
Mortality Among Patients With Early-Onset Atrial Fibrillation and Rare Variants in Cardiomyopathy and Arrhythmia Genes (2022) (7)
Immediate‐ versus controlled‐release disopyramide: Importance of saturable binding (1993) (7)
Himalayan T Waves in the Congenital Long-QT Syndrome (2005) (7)
KCNQ1 and Long QT Syndrome in 1/45 Amish (2020) (6)
LQT 3 Mutant New Mechanism Contributing to Drug-Induced Arrhythmia : Rescue of a Misprocessed (2005) (6)
Arrhythmias as Presentation of Genetic Cardiomyopathy. (2022) (6)
A Bayesian method to estimate variant-induced disease penetrance (2020) (6)
Pharmacologic evaluation of standard and controlled-release disopyramide. (1987) (6)
A Prolonged QTc Interval (1989) (6)
Abstract 4412: High Density tagSNP Candidate Gene Analysis Identifies IKs as a Major Modulator of Genetic Susceptibility to Drug Induced Long QT Syndrome (2008) (6)
Rare variants in genes encoding the cardiac sodium channel and associated compounds and their impact on outcome of catheter ablation of atrial fibrillation (2017) (6)
Whole Genome Sequencing Identifies CRISPLD2 as a Lung Function Gene in Children with asthma. (2019) (6)
The Antiarrhythmic Activity of Meobentine Sulfate in Man (1984) (6)
Clinical Features Associated With Nascent Left Ventricular Diastolic Dysfunction in a Population Aged 40 to 55 Years. (2018) (6)
Genetic variation in the UGT1A locus is associated with simvastatin efficacy in a clinical practice setting. (2014) (6)
DDIWAS: High-throughput electronic health record-based screening of drug-drug interactions (2021) (6)
Genetics Primer for the General Cardiologist Pharmacogenomics The Genetics of Variable Drug Responses (2011) (6)
Online supplemental data Blocking SCN 10 A channels in heart reduces late sodium current and is antiarrhythmic (2012) (6)
Real-time clinical note monitoring to detect conditions for rapid follow-up: A case study of clinical trial enrollment in drug-induced torsades de pointes and Stevens-Johnson syndrome (2020) (6)
Recainam dose titration and pharmacokinetics in patients with resistant arrhythmias (1989) (6)
Defining a Contemporary Ischemic Heart Disease Genetic Risk Profile Using Historical Data (2016) (6)
Mexiletine for resistant ventricular tachycardia: Comparison with lidocaine and enhancement of efficacy by combination with quinidine (1980) (6)
Genome-Wide Assessment for Genetic Variants Associated with Ventricular Dysfunction after Primary Coronary Artery Bypass Graft Surgery (2011) (5)
Integrating EMR-Linked and In Vivo Functional Genetic Data to Identify New Genotype-Phenotype Associations (2014) (5)
Quinidine in the Management of Recurrent Ventricular Arrhythmias: A Reappraisal. (2021) (5)
Images in cardiovascular medicine. Himalayan T waves in the congenital long-QT syndrome. (2005) (5)
QT Bumps: Unraveling the Mechanisms (2001) (5)
Personalized medicine to treat arrhythmias. (2014) (5)
Non-pulmonary vein mediated atrial fibrillation: A novel sub-phenotype (2017) (5)
CNV Association of Diverse Clinical Phenotypes from eMERGE reveals novel disease biology underlying cardiovascular disease. (2019) (5)
Cardiovascular Drugs Review of Mechanisms and Clinical Applications (1998) (5)
Evaluation of a Novel System to Enhance Clinicians' Recognition of Preadmission Adverse Drug Reactions (2018) (5)
Recurrent Ventricular Tachycardia in the Absence of Overt Heart Disease: Clinical Characteristics and Response to Drug Therapy (1981) (5)
Abstract 15518: Novel SNPs Associated with Warfarin Dose in a Large Multicenter Cohort of African Americans: Genome Wide Association Study and Replication Results (2011) (5)
Genomic contributors to atrial electroanatomical remodeling and atrial fibrillation progression: Pathway enrichment analysis of GWAS data (2016) (5)
Genome‐Wide Approach to Measure Variant‐Based Heritability of Drug Outcome Phenotypes (2021) (5)
The effect of sildenafil on QT interval in healthy men (2001) (5)
Bidirectional Mendelian randomization supports bidirectional causality between telomere length and clonal hematopoiesis of intermediate potential (2021) (5)
Genome-and Phenome-Wide Analysis of Cardiac Conduction Identifies Markers of Arrhythmia Risk Running title : Ritchie et al . ; QRS GWAS and PheWAS in electronic records (2013) (5)
Sunday, 26 August 2012 (2012) (5)
Clonal hematopoiesis is driven by aberrant activation of TCL1A (2021) (5)
Pharmacokinetic and Pharmacological Aspects of Polymorphic Drug Oxidation in Man (1984) (5)
Considerations for Drug Interactions on QTc in Exploratory COVID-19 (Coronavirus Disease 2019) Treatment (2020) (5)
Ethical and practical challenges to studying patients who opt out of large-scale biorepository research. (2013) (5)
Cardiovascular and Renal Advisory Panel of the FDA. (1998) (5)
Genetic determinants of variability in warfarin response after the dose-titration phase (2016) (5)
Phenotypic debrisoquine 4-hydroxylase activity among extensive metabolizers is unrelated to genotype as determined by the Xba-I restriction fragment length polymorphism. (1991) (5)
Leveraging Human Genetics to Identify Safety Signals Prior to Drug Marketing Approval and Clinical Use (2020) (5)
Rare Non-coding Variation Identified by Large Scale Whole Genome Sequencing Reveals Unexplained Heritability of Type 2 Diabetes: Trans-Omics for Precision Medicine (TOPMed) Program (2020) (5)
Genetic Testing for Early Onset Atrial Arrhythmias Changes Clinical Management: 2 Cases of Cardiac Emerinopathy. (2021) (4)
Mutations in an alternately processed sodium channel beta-1 subunit associated with Brugada syndrome and cardiac conduction defect (2007) (4)
Common KCNH2 Polymorphism (K897T) as a genetic modifier of congenital long QT syndrome (2005) (4)
Pharmacogenetic-Based Dosing of Warfarin (2008) (4)
Treatment of ventricular arrhythmias in the failing heart: pharmacologic and clinical considerations. (1985) (4)
Etravirine(Intelence) for HIV infection. (2008) (4)
Drug‐Induced Sudden Death (2009) (4)
366 Circ Arrhythm Electrophysiol June 2014 Genetics and the Brugada ECG (4)
Drug interactions with simvastatin. (2008) (4)
A Granisetron Patch (Sancuso) (2008) (4)
Polygenic Risk Score to Identify Subclinical Coronary Heart Disease Risk in Young Adults (2021) (4)
The reckoning: The return of genomic results to 1444 participants across the eMERGE3 Network. (2022) (4)
Variants in ADRB1 and CYP2C9: Association with Response to Atenolol and Losartan in Marfan Syndrome. (2020) (4)
366 Circ Arrhythm Electrophysiol June 2014 Genetics and the Brugada ECG (4)
High-throughput framework for genetic analyses of adverse drug reactions using electronic health records (2021) (4)
Antiarrhythmic Therapy: Clinical Pharmacology Update (1984) (4)
Common Ancestry-specific Ion Channel Variants Predispose to Drug-induced Arrhythmias. (2022) (4)
Methylnaltrexone (Relistor) for opioid-induced constipation (2008) (4)
Use of Mexiletine in Combination with Other Anti arrhythmic Drugs (1986) (4)
Real-time visualization of titin dynamics reveals extensive reversible photobleaching in human induced pluripotent stem cell-derived cardiomyocytes. (2019) (4)
Genetic testing in subjects with no clinical abnormality: the tip of a huge iceberg. (2011) (4)
Clinical pharmacology of old and new antiarrhythmic drugs. (1985) (4)
Multiple mechanisms underlie increased cardiac late sodium current. (2019) (4)
Exploiting ion channel structure to assess rare variant pathogenicity. (2018) (4)
Kcnj11 Ablation Is Associated With Increased Nitro-Oxidative Stress During Ischemia-Reperfusion Injury: Implications for Human Ischemic Cardiomyopathy (2017) (4)
P1-22: Persistent atrial fibrillation is associated with reduced risk of Torsades de Pointes in patients with drug-induced long QT syndrome (2006) (4)
Mutations in RPL3L and MYZAP increase risk of atrial fibrillation (2017) (3)
Rare Variation in Drug Metabolism and Long QT Genes and the Genetic Susceptibility to Acquired Long QT Syndrome (2022) (3)
Gating-dependent mechanisms for flecainide intolerance in SCN5A-linked arrhythmia syndromes (2001) (3)
Author Correction: The mutational constraint spectrum quantified from variation in 141,456 humans (2021) (3)
Summary The T-Box transcription factor Tbx 5 is required for the patterning and maturation of the murine cardiac conduction system (2004) (3)
The Brugada ECG and Schizophrenia (2014) (3)
Fundamental Cardiovascular Research: Returns on Societal Investment: A Scientific Statement From the American Heart Association. (2017) (3)
Arrhythmia / Electrophysiology Striking In Vivo Phenotype of a Disease-Associated Human SCN 5 A Mutation Producing Minimal Changes in Vitro (2011) (3)
16Ethnicity and phenotype in the SCN5A E1784K mutation (2014) (3)
A common polymorphism in KCNH2 (HERG) eliminates gender differences in drug-induced QT prolongation (2005) (3)
Lacosamide for epilepsy. (2009) (3)
Probing the arrhythmogenic substrate. (2006) (3)
Multi-ethnic genome-wide association study for atrial fibrillation (2018) (3)
Abstract 1200: QT-Prolonging Medication Prescription Tendencies In A Cohort Of Hospitalized Patients With Known Long QT Intervals (2008) (3)
Temporal changes in genetic admixture are linked to heterozygosity and health diagnoses in humans (2019) (3)
Tocainide and mexiletine. Orally effective lidocaine analogues. (1985) (3)
Editiorial Commentary: Genomics and drug discovery: The next frontier in precision medicine. (2017) (3)
Estimating the Posttest Probability of Long QT Syndrome Diagnosis for Rare KCNH2 Variants (2021) (3)
Robust, flexible, and scalable tests for Hardy-Weinberg Equilibrium across diverse ancestries (2020) (3)
Monday, 27 August 2012 (2012) (3)
Coding variants in RPL 3 L and MYZAP increase risk of atrial fi brillation (2018) (3)
ABO O blood group as a risk factor for platelet reactivity in heparin-induced thrombocytopenia (2022) (3)
Genomic Medicine Year in Review: 2020. (2020) (3)
Mirror, mirror on the wall ... stereochemistry in therapeutics. (1994) (3)
Genetic thyroid stimulating hormone regulation of atrial fibrillation risk is mediated through an effect on height. (2021) (3)
SCN 5 A Variation Is Associated With Electrocardiographic Traits in the Jackson Heart Study (2011) (3)
Loss of quinidine gluconate injection in a polyvinyl chloride infusion system. (1996) (3)
A comparative study of different methods for automatic identification of clopidogrel-induced bleedings in electronic health records (2017) (3)
Abstract 2249: Overlap Between LQT3 and Brugada Syndrome: Clinical Features in a Common Mutation and Underlying Biophysical Mechanisms (2007) (3)
Abstract 18578: Replication of a Risk Prediction Model for Ambulatory Incident Atrial Fibrillation Using Electronic Medical Record (2012) (3)
Dominant negative effects of SCN5A missense variants (2021) (3)
Sunscreens: An update (2008) (2)
Prevention of venous thromboembolism in orthopedic surgery. (2008) (2)
Total Suppression of Ventricular Arrhythmias by Encainide: Pharmacokinetic and Electrocardiographic Characteristics (1981) (2)
Scientific Engagement at FDA: A Report to the FDA Science Board from the Scientific Engagement Subcommittee (2016) (2)
NPPA Gain-of-Function Mutation Associated with Familial Atrial Fibrillation (2009) (2)
Androgenic effects on ventricular repolarization: A translational study from the international pharmacovigilance database to iPSC-cardiomyocytes. (2020) (2)
Novel mechanism in cardiac injury: immune checkpoints (2020) (2)
Erratum: Large-scale analyses of common and rare variants identify 12 new loci associated with atrial fibrillation (2017) (2)
Results of Prospective Trial to Determine Optimal Patient Positioning Prone vs. Supine for Whole Breast Radiation (2008) (2)
Genome-wide association study of platelet factor 4/heparin antibodies in heparin-induced thrombocytopenia (2022) (2)
Clinical significance of the ECG interval prolongation accompanying effective encainide therapy (1980) (2)
2-Hydroxybenzylamine (2-HOBA) to prevent early recurrence of atrial fibrillation after catheter ablation: protocol for a randomized controlled trial including detection of AF using a wearable device (2021) (2)
Replication of SCN5A Associations with Electrocardiographic Traits in African Americans from Clinical and Epidemiologic Studies (2014) (2)
Commotio cordis due to high-velocity projectile ejected from an industrial lawnmower (2015) (2)
Bimatoprost 0.03% solution (latisse) for eyelash enhancement. (2009) (2)
Abstract 4404: Variation in the 4q25 Chromosomal Locus Predicts New-Onset Atrial Fibrillation after Cardiac Surgery (2008) (2)
ACE I/D Polymorphism Modulates Symptomatic Response to Antiarrhythmic Drug Therapy in Patients with Lone Atrial Fibrillation (2007) (2)
Personalized structural biology reveals the molecular mechanisms underlying heterogeneous epileptic phenotypes caused by de novo KCNC2 variants (2022) (2)
Glutamate Receptor Polymorphisms Contribute to Glucocorticoid-Associated Osteonecrosis (2014) (2)
Prospective pharmacokinetically based development of effective infusion regimens for ACC–9358, a new antiarrhythmic drug (1991) (2)
Sapropterin (Kuvan) for phenylketonuria. (2008) (2)
Growing Pains in Cardiovascular Genetics (2018) (2)
Finding a Needle in a QT Interval Big Data Haystack: The Role for Orthogonal Datasets. (2016) (2)
Recent Advances in the Long QT Syndrome (1997) (2)
Genomic medicine year in review: 2021. (2021) (2)
Atrial Fibrillation Is a Complex Trait: Very Complex. (2020) (2)
Functional Assays Reclassify Suspected Splice-Altering Variants of Uncertain Significance in Mendelian Channelopathies (2022) (2)
Association of genetic variants previously implicated in coronary artery disease with age at onset of coronary artery disease requiring revascularizations (2019) (2)
Frequency of benign neutropenia among Black versus White individuals undergoing a bone marrow assessment (2022) (2)
Management of Congenital Long-QT Syndrome: Commentary From the Experts (2021) (2)
Abstract 12560: Targeted Next Generation Exomic Sequencing of Cardiac Electrophysiology Genes in Cases of Drug-Induced Torsades de Pointes (2010) (2)
Modulators of normal ECG intervals identified in a large electronic medical record (2011) (2)
Polygenic risk score for ACE-inhibitor-associated cough based on the discovery of new genetic loci. (2022) (2)
The Study of Pharmacokinetics and Pharmacodynamics as a Tool for Understanding Mechanisms of Antiarrhythmic Drug Action (1995) (2)
ACE I/D polymorphism modulates response to antiarrhythmic drug therapy in patients with atrial fibrillation (2005) (2)
Abstract 19509: Identifying Genotype-Phenotype Relations in Electronic Medical Record Systems: Application to Warfarin Pharmacogenomics. (2010) (2)
The Case for Expanding the FDA Box Warning on Clopidogrel to CYP2C19 Intermediate Metabolizers (2021) (2)
The 3D spatial constraint on 6.1 million amino acid sites in the human proteome (2021) (2)
Proactive variant effect mapping to accelerate genetic diagnosis for pediatric cardiac arrest (2022) (2)
Tocilizumab (Actemra) for giant cell arteritis. (2017) (2)
Association Genetics and Cardiovascular Disease : A Policy Statement From the American Heart (2012) (2)
Tetrabenazine (Xenazine) for Huntington's chorea. (2009) (2)
Recombinant human antithrombin (ATryn). (2009) (2)
Misprocessing as a mechanism for phenotypic variability in LQT3 (2005) (2)
Veratridine Can Bind to a Site at the Mouth of the Channel Pore at Human Cardiac Sodium Channel NaV1.5 (2022) (2)
When should QT be measured? Summer solstice or Christmas Eve? (2007) (2)
Arrhythmia genetics: Not dark and lite, but 50 shades of gray. (2018) (2)
Clinical Pharmacology of the New Antiarrhythmic Encainide (1984) (2)
Potassium channels as targets for drug action (1993) (1)
Letter regarding article by Darbar et al, "Unmasking of Brugada syndrome by lithium" - Response (2006) (1)
Abstract 17900: A Common Single Nucleotide Polymorphism Associated With Atrial Fibrillation Modulates Symptomatic Response To Antiarrhythmic Drug Therapy (2010) (1)
Author Correction: Landscape of multi-nucleotide variants in 125,748 human exomes and 15,708 genomes (2021) (1)
Valproic acid delayed release (Stavzor). (2009) (1)
Transcriptional Dysregulation Underlies Both Monogenic Arrhythmia Syndrome and Common Modifiers of Cardiac Repolarization (2022) (1)
Association of longitudinal activity measures and diabetes risk: an analysis from the NIH All of Us Research Program. (2022) (1)
An overview of contemporary approaches to antiarrhythmic therapy. (1999) (1)
Publisher Correction: Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries (2018) (1)
Arrhythmia Risk Genome-and Phenome-Wide Analyses of Cardiac Conduction Identifies Markers of (2013) (1)
Blunted verp response to isoproterenol in mink (KCNE1) knockout mice (2005) (1)
Response to “Clinically Actionable Genotypes Among Brazilians” (2014) (1)
Pharmacologic information required for design of programmed electrical stimulation protocols. (1986) (1)
Delayed Activation and Retrograde Propagation in Cardiac Muscle: Implication of Virtual Electrode Effects (2000) (1)
Adverse Drug Events (2017) (1)
Silodosin (Rapaflo) for benign prostatic hyperplasia. (2009) (1)
Pharmacology of encainide metabolites in man (1985) (1)
A memorable experience. (2007) (1)
Genome-Wide Association Analysis Identifies 3 Common Variants Predisposing to Brugada Syndrome, a Rare Disease with High Risk of Sudden Cardiac Death (2013) (1)
Antiarrhythmic drugs. Clinical pharmacology of the old and the new agents. (1985) (1)
Drugs for cognitive loss and dementia. (2017) (1)
Zingo for local analgesia in children. (2008) (1)
Machine Learning Challenges in Pharmacogenomic Research (2021) (1)
ECGs before stimulants in children. (2008) (1)
Editorial: Who Needs a New Journal? (1997) (1)
Abstract 19353: Genome Wide Association Studies of Heart Failure With Reduced and Preserved Ejection Fraction Point to Different Genetic Architectures (2017) (1)
Dronedarone (Multaq) for atrial fibrillation. (2009) (1)
Genetic Determinants of Body Mass Index and Fasting Glucose Are Mediators of Grade 1 Diastolic Dysfunction (2022) (1)
Association of Genetic Risk of Obesity with Postoperative Complications Using Mendelian Randomization (2019) (1)
Red yeast rice (2009) (1)
Cardiac Arrhythmia 1 Systems biology and cardiac arrhythmias (2012) (1)
Bendamustine (Treanda) for CLL and NHL. (2008) (1)
Transcript expression-aware annotation improves rare variant interpretation (2020) (1)
Abstract 14477: Integrating Patient-Specific Cardiomyocyte Function With Population Multi-omics Identifies a Novel Arrhythmia Pathway (2017) (1)
Relationship to Potassium and Cycle Length (2005) (1)
Sodium Channel Variants Associated with Atrial Fibrillation Exhibit Abnormal Fast and Slow Inactivation (2010) (1)
Abstract 3395: A Novel Locus on Chromosome 5 for Familial Atrial Fibrillation Associated with Prolonged Signal-Averaged P-wave (2006) (1)
PR interval genome-wide association meta-analysis identifies 50 loci associated with atrial and atrioventricular electrical activity (2018) (1)
Diagnostic yield : the rate at which a particular diagnostic test establishes a molecular diagnosis in a population of patients INTRODUCTION (2016) (1)
Abstract 2197: A Genotype Dependent Intermediate ECG Phenotype in Patients with Persistent Lone Atrial Fibrillation (2007) (1)
A Bayesian method using sparse data to estimate penetrance of disease-associated genetic variants (2019) (1)
Screening for oral cancer (2009) (1)
Deep Mutational Scan of a cardiac sodium channel voltage sensor (2019) (1)
Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop Sudden Cardiac Death Prediction and Prevention: Report From a National (2010) (1)
Using systems approaches to address challenges for clinical implementation of pharmacogenomics (2015) (1)
Whole-genome association analyses of sleep-disordered breathing phenotypes in the NHLBI TOPMed program (2021) (1)
Continuous Bayesian Variant Interpretation Accounts for Incomplete Penetrance among Mendelian Cardiac Channelopathies (2022) (1)
P1591Cardiovascular toxicity of ibrutinib: a pharmacovigilance study (2019) (1)
Genome-Wide Association Study Identifies Variation in ABO As Risk Factor for Platelet Reactivity in Heparin-Induced Thrombocytopenia (2020) (1)
Long QT Syndrome and Potentially Pathogenic Genetic Variants--In Reply. (2016) (1)
Daily Step Counts Before and After the COVID-19 Pandemic Among All of Us Research Participants (2023) (1)
Abstract 2684: Modulators of Normal ECG Intervals Identified in a large Electronic Medical Record (2009) (1)
Evidence for Pharmacogenomic Effects on Risperidone Outcomes in Pediatrics. (2020) (1)
Correction: Enabling Genomic-Phenomic Association Discovery without Sacrificing Anonymity (2013) (1)
Intravenous Ibuprofen (Caldolor) (2010) (1)
Interactive network-based clustering and investigation of multimorbidity association matrices with associationSubgraphs (2022) (1)
Dominant negative effects of SCN5A missense variants. (2022) (1)
Genome-wide association meta-analysis of PR interval identifies 47 novel loci associated with atrial and atrioventricular electrical activity (2018) (1)
Abstract 4099: Genetic and Clinical Predictors of Response to Rate Control Therapy in Patients with Atrial Fibrillation (2008) (1)
Abstract 15433: Lpa Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins Abstract (2017) (1)
Abstract 15509: Genomwide-Association Identifies a Novel Locus for Anthracycline Cardiotoxicity (2013) (1)
Cardiovascular Genetics and Genomics (2009) (1)
My Cousin Also Has Atrial Fibrillation: Family Relationships in a Genomic Era. (2019) (1)
Benefits and risks of combined burst pacing and drug therapy of recurrent ventricular tachycardia (1981) (1)
Loperamide Induced Recurrent Torsades de Pointes: A Case Report (2021) (1)
Application of Pharmacologic Principles in the Evaluation of New Antiarrhythmic Agents (1983) (1)
Returning integrated genomic risk and clinical recommendations: the eMERGE study. (2023) (1)
Intravenous 3‐Methoxy‐O‐Desmethyl‐Encainide in Reentrant Supraventricular Tachycardia: A Randomized Double‐Blind Placebo‐Controlled Trial in Patients Undergoing EP Study (1991) (1)
Abstract 637: A Pharmacogenetic Screen for Modifiers of Drug Induced QT Prolongation Reveals 15 Novel Genes. (2007) (1)
Common SCN 10 A variants modulate PR interval and heart rate response during atrial fibrillation (2014) (1)
Antiarrhythmic Drugs: (2003) (1)
Abstract 356: Loss of Function Mutations of Sodium Channel Beta-1 and Beta-2 Subunits Associated with Atrial Fibrillation and ST-segment Elevation (2007) (1)
Abstract 18723: Genetic Variants Associated with QT Prolongation in Patients Exposed to Sotalol: A Genome Wide Association Study (2012) (1)
pharmacokinetic consequences Polymorphism of propafenone metabolism and disposition in man: clinical and (2011) (1)
Electrophysiologic Effects of Azithromycin in Cardiomyocytes (2013) (1)
Abstract 17726: Comprehensive Evaluation of QT Interval During Abrupt Changes in Heart Rate and Associated Neurohormonal and Inflammatory Markers (2014) (1)
Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries (2018) (1)
Toxicology and Genetics of Adverse Drug Events (2009) (1)
Author Correction: Characterising the loss-of-function impact of 5’ untranslated region variants in 15,708 individuals (2021) (0)
CLINICAL PHENOTYPES ASSOCIATED WITH POTENTIALLY PATHOLOGIC VARIANTS IN CARDIOMYOPATHY-ASSOCIATED GENES IN A LARGE ELECTRONIC MEDICAL RECORD (2015) (0)
Author Correction: Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility (2022) (0)
Cardiovascular pharmacogenetics: opportunities and challenges (2012) (0)
Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium (2017) (0)
Abstract 12009: A Prospective Randomized Placebo-Controlled Crossover Trial of Flecainide for Catecholaminergic Polymorphic Ventricular Tachycardia (2016) (0)
Abstract 17782: Both Common and Rare SCN10A Variants Associated with Brugada Syndrome Displayed an Increase in Late Nav1.8 Sodium Currents in ND 7/23 cells (2014) (0)
A study paradigm integrating prospective epidemiologic cohorts and electronic health records to identify disease biomarkers (2018) (0)
Ciclesonide (Alvesco)-a new inhaled corticosteroid for asthma. (2008) (0)
Comparing medical history data derived from electronic health records and survey answers in the All of Us Research Program (2022) (0)
BASIC AND TRANSLATIONAL—BILIARY Four Susceptibility Loci for Gallstone Disease Identified in a Meta-analysis of Genome-Wide Association Studies (2016) (0)
Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium (2021) (0)
Abstract 1244: Expression of the Cardiac Sodium Channel Nav1.5 is Required for the Differentiation of Cardiomyocyte Progenitor Cells in vivo (2006) (0)
Impact of Recent Molecular Studies on Evaluation of Ventricular Arrhythmias (2004) (0)
Clonal haematopoiesis and risk of chronic liver disease (2023) (0)
Abstract 18516: Common Atrial Fibrillation Susceptibility Alleles Enhance Clinical Risk Prediction Model for Postoperative Atrial fibrillation (2012) (0)
Running title: Shoemaker et al.; Genetic Variants and Response to AF Ablation (2017) (0)
Heat and transdermal fentanyl (2009) (0)
B-PO04-136 RELATIONSHIP BETWEEN ATRIAL FIBRILLATION AND DECLINING RENAL FUNCTION (2021) (0)
Abstract 16519: A Common Variant at the 16q22 Atrial Fibrillation Risk Locus is Unexpectedly Associated with Reduced Left Atrial Size (2012) (0)
Uterine fibroid polygenic risk score (PRS) associates and predicts risk for uterine fibroid (2022) (0)
SCN10A Rare Variants Associated with Atrial Fibrillation and Slow Ventricular Rates Reveal Increased Late Sodium Current (2012) (0)
Administration: Real Life Is Complicated Responding to the Clopidogrel Warning by the US Food and Drug (2011) (0)
Abstract 17778: Cellular and Functional Defects Contributing to Dilated Cardiomyopathy in SCN5A D1275N Mice (2014) (0)
Chapter 51 – Pharmacogenomics of Cardiac Arrhythmias and Impact on Drug Therapy (2004) (0)
A phenome-wide association study to discover pleiotropic effects of PCSK9, APOB, and LDLR (2019) (0)
Pneumococcal vaccination of adults: polysaccharide or conjugate. (2009) (0)
163 Genetic Modifiers in Carriers of the SCN5A E1784K Mutation with Variable Phenotypic Expression - Long QT3 / Brugada Syndrome Overlap Disease (2014) (0)
Site-Directed KCNQ 1 Mutagenesis and Transient Transfection in Chinese Hamster Ovary Cells (2009) (0)
Abstract 3350: Plasminogen Activator Inhibitor-1 as a Predictor of Postoperative Atrial Fibrillation Following Cardiopulmonary Bypass (2006) (0)
A Genotype Dependent Intermediate ECG Phenotype in Patients with Persistent Lone Atrial Fibrillation Husser : Genotype ECG-phenotype correlation in AF (2009) (0)
Heart failure clinical care analysis uncovers risk reduction opportunities for preserved ejection fraction subtype (2021) (0)
Abstract 948: An Allosteric Mechanism for Drug Block of a Cardiac Potassium Channel (2007) (0)
Genomics of Cardiac Arrhythmias (2017) (0)
Clinical Pharmacodynamics of Cardiovascular Agents: Focus on Sudden Cardiac Death (1993) (0)
Coming Soon in The Medical Letter: Lisdexamfetamine dimesylate (Vyvanse) for ADHD Lybrel — A New Contraceptive Pill Lapatinib (Tykerb) for Breast Cancer (2007) (0)
Dynamic incorporation of multiple in silico functional annotations empowers rare variant association analysis of large whole-genome sequencing studies at scale (2020) (0)
Incessant atrial and ventricular tachycardias associated with an SCN5A mutation (2021) (0)
Abolition of ventricular arrhythmias during chronic oral therapy with encainide in man (1980) (0)
Abstract 14459: Genome-Wide Association Analysis Identifies 3 Common Variants Predisposing to Brugada Syndrome, a Rare Disease With High Risk of Sudden Cardiac Death (2013) (0)
Characterising the loss-of-function impact of 5’ untranslated region variants in 15,708 individuals (2020) (0)
Title : A case study evaluating the portability of an executable computable phenotype algorithm across multiple institutions and EHR environments Corresponding (2018) (0)
High-Throughput Investigation of Contractile and Electrophysiological Properties of Optically Stimulated hiPSC-CM Monolayers (2018) (0)
REMEMBER THE TITIN: CARDIAC SARCOIDOSIS AND A LIKELY PATHOGENIC VARIANT IN TTN IN A PATIENT PRESENTING WITH VENTRICULAR TACHYCARDIA (2023) (0)
Abstract 13476: Association of HLA-DRB3*01:01 With Heparin-Induced Thrombocytopenia (2015) (0)
Abstract 14052: Feasibility of Whole Genome Sequencing for Atrial Fibrillation (2016) (0)
A structural variation reference for medical and population genetics (2020) (0)
Arrhythmias Due to Monogenic Disorders (2010) (0)
Abstract 14785: The Reactive Lipid Mediators Isolevuglandins Promote Atrial Fibrillation Mediated by Inflammation (2020) (0)
Response to Letter Regarding Article, “Cardiac Sodium Channel (SCN5A) Variants Associated with Atrial Fibrillation” (2008) (0)
Highlights From the Circulation Family of Journals. (2017) (0)
P6590Androgenic effects on ventricular repolarization: a translational study from pharmacovigilance databases to iPSC-cardiomyocytes (2019) (0)
Bibliography of One Hundred Key Papers 255 Summaries of Ten Seminal Papers - (2002) (0)
New Leaders in Cardiovascular Science (2014) (0)
Metabolic Syndrome and Risk of Development of Atrial Fibrillation The Niigata Preventive Medicine Study Arrhythmia/Electrophysiology (2010) (0)
Abstract 19317: Real-Time Visualization of Endogenous Titin Dynamics in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes (2016) (0)
ST ELEVATION AS AN ECG ENDOPHENOTYPE FOR ATRIAL FIBRILLATION PATIENTS HARBORING RARE SODIUM CHANNEL SUBUNIT GENE VARIANTS (2014) (0)
Abstract 2274: Rescue of a Misprocessed LQT3 Mutation in Mouse Heart (2009) (0)
Deep learning analysis of drug-induced ECG changes to inform arrhythmia risk and improve diagnosis of congenital long QT syndrome (2021) (0)
of the Class Ill Antiarrhythmic Agent Sematilide in Patients with Arrhythmias (1992) (0)
Pharmacogenomics of Cardiac Arrhythmias (2018) (0)
Aberrant activation of TCL1A promotes stem cell expansion in clonal haematopoiesis (2023) (0)
B-AB13-05 HIGH-THROUGHPUT PATCH CLAMP OF INDEL AND MISSENSE VARIANTS IN SCN5A (2021) (0)
Dutasteride (Avodart) with tamsulosin (Flomax) for benign prostatic hyperplasia. (2008) (0)
Abstract 16179: Concordance Between Machine Learning-based Methods of Atrial Fibrillation Subtyping in 49,905 Individuals and Relationship to Genetically Predicted Af Risk and Inflammation (2020) (0)
Author Correction: Evaluating drug targets through human loss-of-function genetic variation (2021) (0)
Abstract 18012: Modeling of a Rare SCN10A Variant (A1886V) Linked with Early-Onset Atrial Fibrillation Shortens Atrial Action Potential Duration (2014) (0)
P3-29: Phenotypic characterization of patients with familial atrial fibrillation (2006) (0)
Principles of Pharmacogenetics and Pharmacogenomics: Genomics of the Drug-Induced Long-QT Syndrome (2012) (0)
IMPROVE AND ENHANCE EDUCATION DELIVERY AND THE ROLE OF TECHNOLOGY IN THE SICKLE CELL TRANSITION POPULATION (2021) (0)
Rufinamide (Banzel) for epilepsy. (2009) (0)
Pharmacokinetics of Anti-Arrhythmic Agents in Acute Myocardial Infarction (1984) (0)
Publisher Correction: Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries (2018) (0)
Predictive models for abdominal aortic aneurysms using polygenic scores and PheWAS-derived risk factors (2022) (0)
Abstract 15725: Next-generation-based Mutation Screening Identifies A Dysfunctional Calcium Channel {beta}-subunit Mutation In Short QT Syndrome (2010) (0)
Adapalene-Benzoyl Peroxide (Epiduo) for Acne (2009) (0)
A rare variant on a common risk haplotype of HFE causes increased risk of hereditary hemochromatosis (2019) (0)
Abstract 12933: A Genome-Wide Association Analysis to Identify Genomic Modulators of Rate Control Therapy in Patients with Atrial Fibrillation (2011) (0)
Nkx2-5 mutation causes anatomic hypoplasia of the conduction system (2004) (0)
Drugs for MRSA with reduced susceptibility to vancomycin. (2009) (0)
Author Correction: Inherited causes of clonal haematopoiesis in 97,691 whole genomes (2021) (0)
Heritability and genome-wide association study of benign prostatic hyperplasia (BPH) in the eMERGE network (2019) (0)
Running title: Genome-wide association study in long QT syndrome (2020) (0)
2 Future Challenge in Brugada syndrome : Gender and Ethnic Differences(Brugada Syndrome:From Cell to Bedside,Plenary Session 2 (PL2) (A),The 70th Anniversary Annual Scientific Meeting of the Japanese Circulation Society) (2006) (0)
Abstract 13007: Common and Rare Variants in SCN10A Associated with Atrial Fibrillation (2011) (0)
PharmGKB Submission Update: VII. PAT Submissions of Genetic Variation in KCND3 to the PharmGKB Network (2006) (0)
Expert Answers to Three Key Questions (2011) (0)
Improved high-performance liquid chromatographic assay for encainide and its metabolites in human body fluids. (1989) (0)
The polygenic architecture of left ventricular mass mirrors the clinical epidemiology (2020) (0)
Author Correction: A structural variation reference for medical and population genetics (2021) (0)
Quantifying the phenome‐wide disease burden of obesity using electronic health records and genomics (2022) (0)
Abstract 14663: High Rate of Arrhythmia Diagnoses Following Return of Pathogenic/likely Pathogenic Variants in an Unselected Population (2020) (0)
A Patient With Elevated Plasma High Density Lipoprotein (HDL) and Facial Flushing (2017) (0)
Family Screening After Sudden Death in a Population-Based Study of Children. (2022) (0)
Abstract 96: A Unique Jervell Lange-Nielsen Syndrome Mutation Modeled in Induced Pluripotent Stem Cell Derived Cardiomyocytes (2015) (0)
Abstract 12219: Arrhythmia-associated Variants in the SCN5A Promoter and Regulatory Regions (2012) (0)
Reprint of Editiorial Commentary: Genomics and drug discovery: The next frontier in precision medicine. (2017) (0)
Clinical and Genetic Predictors of Cutaneous Squamous Cell Carcinoma in Kidney and Heart Transplant Recipients.: Abstract# A516 (2014) (0)
Abstract 17956: External Validation of a Prediction Model for the Development of Atrial Fibrillation in a Repository of Electronic Medical Records (2014) (0)
The All of Us Research Program Researcher Workbench: Cloud based access and analytics to advance precision medicine (2020) (0)
Brief Communication Quinidine Delays I K Activation in Guinea Pig Ventricular Myocytes (2005) (0)
Author Correction: Transcript expression-aware annotation improves rare variant interpretation (2021) (0)
Abstract 11267: Ibrutinib Treatment Results in Arrhythmia in Atrial-Specific Human Ipsc-Derived Cardiomyocytes (2021) (0)
Another once-daily formulation of tramadol (Ryzolt). (2010) (0)
Abstract 5301: Flecainide Blocks Cardiac Ryanodine Channels and Prevents Catecholaminergic Ventricular Tachycardia in Cardiac Calsequestrin Null Mice (2008) (0)
Olapatadine (Patanase) nasal spray for allergic rhinitis. (2008) (0)
Abstract 1965: Common Variants in KCNN3 Are Associated With Early-Onset Atrial Fibrillation (2009) (0)
Pharmacy and therapeutics committee review of encainide (1987) (0)
Cloud gazing: demonstrating paths for unlocking the value of cloud genomics through cross-cohort analysis (2022) (0)
When a statin fails. (2009) (0)
The genetic determinants of recurrent somatic mutations in 43,693 blood genomes (2023) (0)
Pleiotropy of systemic lupus erythematosus risk alleles and cardiometabolic disorders: A phenome-wide association study and inverse-variance weighted meta-analysis (2021) (0)
IMPORTANCE OF PHARMACOGENETICS TO VARIABILITY IN DRUG RESPONSE (2018) (0)
Abstract 18645: Rare SCN10A Variants Associated With Lone Atrial Fibrillation Modulate Peak and Late Sodium Currents (2013) (0)
Multi-ancestry GWAS of the electrocardiographic PR interval identifies 202 loci underlying cardiac conduction (2020) (0)
Erratum to: A multi-stage genome-wide association study of uterine fibroids in African Americans (2017) (0)
Atrial fibrillation genomics: time to take the next step. (2014) (0)
Coding variants in RPL3L and MYZAP increase risk of atrial fibrillation (2018) (0)
Genomic Medicine Year in Review: 2022. (2022) (0)
SURVEY OF PROVIDER OPINIONS ON GENETIC EVALUATION OF EARLY ONSET ATRIAL FIBRILLATION (2023) (0)
Abstract 4408: Using a Large Electronic Medical Record to Validate 4q25 Variants Conferring Risk for Atrial Fibrillation (2008) (0)
Recurrent Pregnancy Loss and Concealed Long‐QT Syndrome (2021) (0)
Abstract 10418: Complex Action Potential Regulation in Cardiomyocytes from Induced Pluripotent Stem Cells (iPSC-CMs) Reveals a Novel Arrhythmia Susceptibility Mechanism (2021) (0)
Abstract 19099: Genome-Wide Association Study Identifies a Region at Chr 21q21 as a Susceptibility Locus for Ventricular Fibrillation in Acute Myocardial Infarction (2010) (0)
Arrhythmia genetics: Not dark and lite, but fifty shades of grey (2019) (0)
A genome- and phenome-wide association study to identify genetic variants influencing platelet count and volume and their pleiotropic effects (2013) (0)
MUTATIONS IN GENES ENCODING THE CARDIAC SODIUM CHANNEL AND ASSOCIATED COMPOUNDS AND THEIR IMPACT ON OUTCOME OF CATHETER ABLATION FOR ATRIAL FIBRILLATION (2013) (0)
Abstract 11082: Exome Sequencing Implicates the Burden of Rare Potassium Channel Variants in the Risk of Drug Induced Long QT Syndrome (2013) (0)
Divergent Effects of AF or LQTS-Associated HERG Mutations on Endogenous IKr (2010) (0)
Erratum to: A multi-stage genome-wide association study of uterine fibroids in African Americans (2017) (0)
Pulmonary Vein Myocardial Sleeve Length and Its Association With Sex and 4q25/PITX2 Genotype (2023) (0)
Mapping and characterization of structural variation in 17,795 human genomes (2020) (0)
Insulin glargine (Lantus) and cancer risk. (2009) (0)
A multi-stage genome-wide association study of uterine fibroids in African Americans (2017) (0)
Abstract 16470: Morbid Obesity Increases the Risk of Procedural Complications in Patients Undergoing Atrial Fibrillation Ablation (2012) (0)
The All of Us Research Program Researcher Workbench Phenotype Library: Five Disease Implementations (2020) (0)
Two-dimensional In Vivo Experiments (2005) (0)
Response to Numann and Gibson (2012) (0)
Abstract 11449: Influence of Exonic Variation on Heparin-Induced Thrombocytopenia (2014) (0)
Malignant cardiac arrhythmias: pharmacologic considerations (1984) (0)
Proactive Variant Effect Mapping Aids Diagnosis in Pediatric Cardiac Arrest. (2023) (0)
A High-Throughput Genetic Analysis of Common Drug Allergy Labels Using Data from a Large Biobank (2018) (0)
EVALUATION OF THE ASSOCIATION OF THE F2R IVS-14A/T PAR-1 POLYMORPHISM WITH STENT THROMBOSIS AND SUBSEQUENT CARDIOVASCULAR EVENTS IN A COHORT OF CORONARY ARTERY DISEASE PATIENTS (2012) (0)
Enhancing rare variant interpretation in inherited arrhythmias through quantitative analysis of consortium disease cohorts and population controls (2020) (0)
Abstract 1531: SCN5A Promoter and Enhancer Variants associated with Atrial Fibrillation (2008) (0)
Artemether-lumefantrine (Coartem) for treatment of malaria. (2009) (0)
Low-voltage electronic diagnostic devices. (2008) (0)
A Variation Is Associated With Electrocardiographic Traits in the Jackson Heart Study (2011) (0)
P3815A genetic risk score predicts Brugada syndrome phenotype in SCN5A overlap syndrome (2018) (0)
Erratum: Robust replication of genotype-phenotype associations across multiple diseases in an electronic medical record (American Journal of Human Genetics (2010) 86 (560-572)) (2010) (0)
Abstract 2922: KCNQ1 Gain-of-function Mutation Associated With Familial Atrial Fibrillation (2007) (0)
Cardiovascular Pharmacogenetics (2004) (0)
Incidence and clinical features of the quinidine-associated long QT syndrome: Implications for patient care (1987) (0)
The EarCheck Middle Ear Monitor for detection of middle ear effusion in children. (2008) (0)
Wei Atrial Fibrillation in KCNE 1-Null Mice (2005) (0)
Aalborg Universitet Association of genetic variants previously implicated in coronary artery disease with age at onset of coronary artery disease requiring (2019) (0)
Response by Salem et al to Letter Regarding Article, "Androgenic Effects on Ventricular Repolarization: A Translational Study From the International Pharmacovigilance Database to iPSC-Cardiomyocytes". (2020) (0)
Principles of Pharmacogenomics: Focus on Arrhythmias (2007) (0)
Addendum: The mutational constraint spectrum quantified from variation in 141,456 humans (2021) (0)
Cardiac Conduction Common Sodium Channel Promoter Haplotype in Asian Subjects Underlies Variability in (2006) (0)
Modulation of Cardiac Na (cid:49) Current Phenotype by (cid:98) 1 -Subunit Expression (1998) (0)
A shock in time. (2007) (0)
Abstract 1964: A Genome-Wide Association Study in Icelanders Identifies a Novel Sequence Variant on Chromosome 16q22 That is Additive to 4q25 Variants for Atrial Fibrillation Risk (2009) (0)
Quinidine in the Management of Recurrent Ventricular Arrhythmias: A Reappraisal (2021) (0)
B-PO03-017 ROLE OF KV11.1 MISTRAFFICKING IN HIGHLY PENETRANT KCNQ1 VARIANTS (2021) (0)
Abstract 1399: Cardiac Calsequestrin Deletion Causes Premature Sarcoplasmic Reticulum Calcium Release and Catecholaminergic Polymorphic Ventricular Tachycardia in Mice (2006) (0)
Oral Session II‐A (OII‐A) (2012) (0)
High-throughput functional mapping of variants in an arrhythmia gene, KCNE1, reveals novel biology (2023) (0)
The impact of damaging epilepsy and cardiac genetic variant burden in sudden death in the young (2023) (0)
Implementing pharmacogenomics to improve drug therapy: where do we stand in 2002 (2002) (0)
Partial Duplication and Poly(A) Insertion in KCNQ1 Not Detected by Next-Generation Sequencing in Jervell and Lange-Nielsen Syndrome. (2016) (0)
Approaches to Identifying Patients for Genomic Study Adding genomic studies into a large randomized trial (2012) (0)
Familial Hypercholesterolemia in the Electronic Medical Records and Genomics Network: Prevalence, Penetrance, Cardiovascular Risk, and Outcomes After Return of Results (2023) (0)
Abstract 11966: Exome Sequencing of Remotely Related Individuals Plus Bioinformatic Analysis Identifies Rbm20 as a Cause Of DCM in a Large Pedigree as Well as Hdac7 a Potential Genetic Modifier (2012) (0)
A Common β-Adrenergic Receptor Polymorphism Modulates Response to Rate Control in Atrial Fibrillation (2011) (0)
Molecular Genetics of the Acquired Long QT Syndrome (2000) (0)
How does Congestive Heart Failure Alter Response to Drugs (1987) (0)
B-PO05-026 AGE-RELATED PREVALENCE OF RARE DISEASE-ASSOCIATED VARIANTS IN 1293 PATIENTS WITH EARLY-ONSET ATRIAL FIBRILLATION (2021) (0)
Approaches to Identifying Patients for Genomic Study Adding genomic studies into a large randomized trial (2012) (0)
Author Correction: Genome-wide association analyses identify new Brugada syndrome risk loci and highlight a new mechanism of sodium channel regulation in disease susceptibility (2022) (0)
John A. Oates: A Founding Father of Clinical Pharmacology (2019) (0)
P2597Heart failure and atrial tachyarrhythmia on abiraterone: a characterization using pharmacovigilance databases (2019) (0)
Long-QT Syndrome (2007) (0)
Novel Therapeutic concepts Drug-induced arrhythmia : pharmacogenomic prescribing ? (2012) (0)
The mutational constraint spectrum quantified from variation in 141,456 humans (2020) (0)
Intracellular Sodium Overload: A System Biology Problem with Implications for Drug Target Identification (2006) (0)
Landscape of multi-nucleotide variants in 125,748 human exomes and 15,708 genomes (2020) (0)
P1-35: The common Angiotensinogen (AGT) polymorphism T207M protects from drug-induced QT prolongation (2006) (0)
Detection of distant familial relatedness in biobanks for identification of undiagnosed carriers of a Mendelian disease variant: application to Long QT Syndrome (2023) (0)
Publisher Correction: Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries (2020) (0)
Abstract 18898: Abnormal Conduction and Arrhythmias Precede the Development of Dilated Cardiomyopathy in D1275n Mutant Mice (2016) (0)
The Genetics of Cardiac Channelopathies: Implications for Therapeutics (2004) (0)
Author Disclosure Table (2009) (0)
Deep-coverage whole genome sequences and blood lipids among 16,324 individuals (2018) (0)
Comprar Cardiovascular Genetics and Genomics | Mariell Jessup | 9781405175401 | Wiley (2009) (0)
Abstract 12067: A Genome Wide Association Study (GWAS) of the Early Repolarization Phenotype in BioVU Implicates Variants at 12q22 (2012) (0)
Molecular and Electrophysiological Mechanisms of Arrhythmias in Hypertrophic Cardiomyopathy (1998) (0)
American Society for Clinical Pharmacology and Therapeutics (1975) (0)
YEAR IN REVIEW Genomic Medicine Year in Review: 2020 (2020) (0)
Response to Letter Regarding Article, “Plasminogen Activator Inhibitor-1 as a Predictor of Postoperative Atrial Fibrillation After Cardiopulmonary Bypass” (2008) (0)
Common clinical risk factors for drug-induced QT prolongation and torsades de pointes Female gender Conditions predisposing to heightened QT prolongation and risk of arrhythmia Heart disease Congestive heart failure Left ventricular hypertrophy Hours following conversion of atrial fibrillation to si (2013) (0)
Genome-Wide Association Study (GWAS) Of Venous Thromboembolism (VTE) In African-Americans From The Electronic Medical Records & Genomics (eMERGE) Networkm (2013) (0)
Genetic determinants of risk and survival in pulmonary arterial hypertension (2018) (0)
Pharmacogenetics and Cardiac Ion Channels (2005) (0)
Genomic screening as a starting point for studies of ion channel structure‐function (2005) (0)
Evaluating drug targets through human loss-of-function genetic variation (2020) (0)
Abstract 1701: Sodium Channel Beta Subunits Modulate Heart Rate, Drug Sensitivity, and Development in Zebrafish Embryos (2006) (0)
Principles of Drug Therapy (2012) (0)
Author Correction: Association of step counts over time with the risk of chronic disease in the All of Us Research Program. (2023) (0)
Abstract 15812: Oxidative Stress Promotes Susceptibility to Atrial Fibrillation in Pitx2 Deficient Mice (2020) (0)
Cornea Farinata and other Variants (2009) (0)
55 – Pharmacogenomics of Cardiac Arrhythmias (2014) (0)
Golimumab (simponi) for inflammatory arthritis. (2009) (0)
Clonal Hematopoiesis of Indeterminate Potential Status is Associated with Left Main Artery Stenosis (2023) (0)
Association of Obesity with Postoperative Complications Using Phenome-Wide Association Studies and Mendelian Randomization (2018) (0)
This Journal feature begins with a case vignette highlighting a common clinical problem. Evidence supporting various strategies is then presented, followed by a review of formal guidelines, when they exist. The article ends with the author's clinical recommendations. Long-QT Syndrome (2008) (0)
QT shortening with exercise in normals: Terminal repolarization does not shorten with exercise (2005) (0)
Mutation Associated With a Malignant Variant ofProgressive Familial Heart (2012) (0)
The effect of LRRK2 loss-of-function variants in humans (2020) (0)
Determination of debrisoquine/sparteine phenotype during chronic propafenone therapy: a new approach using intact conjugates (1990) (0)
Abstract 2456: Chronic Amiodarone Suppresses Ventricular Tachycardia in a Mouse Model of Pediatric Cardiomyopathy (2006) (0)
The Genetics of the Long-QT Syndrome ☆ (2002) (0)
A scalable EHR-based approach for phenotype discovery and variant interpretation for hereditary cancer genes (2021) (0)
Suppression of complex ventricular arrhythmias by timolol (1982) (0)
A de novo arrhythmogenic Nav1.5 variant, E171Q, causes multiple biophysical defects. (2023) (0)
Abstract 20688: A Phenome-Wide Association Study to Assess Pleiotropic Effects of LPA (2017) (0)
A research agenda to support the development and implementation of genomics-based clinical informatics tools and resources (2022) (0)
High-throughput discovery of trafficking-deficient variants in the cardiac potassium channel KCNH2: Deep mutational scan of KCNH2 trafficking (2020) (0)
Cardiovascular Pharmacogenomics PDATE (2003) (0)
3 PHARMACOKINETICS OF ANTI-ARRHYTllllIC AGENTS IN ACUTE (1984) (0)
Abstract 2378: Genetics of the Initial Anticoagulant Response to Warfarin - a Prospective Study (2006) (0)
Variant-specific inflation factors for assessing population stratification at the phenotypic variance level (2021) (0)
Reply to Ward and Colleagues’ Comment on “Using Human Experiments of Nature to Predict Drug Safety Issues: An Example with PCSK9 Inhibitors” (2018) (0)
and the International Society for Computerized Electrocardiology Endorsed by the American Association of Critical-Care Nurses Foundation Cardiology From the American Heart Association and the American College of Prevention of Torsade de Pointes in Hospital Settings: A Scientific Statement (2010) (0)

This paper list is powered by the following services:

Other Resources About Dan Roden

en.wikipedia.org

What Schools Are Affiliated With Dan Roden?

Dan Roden is affiliated with the following schools:

Dan Roden's Academic­Influence.com Rankings

Dan Roden's Degrees

Why Is Dan Roden Influential?

Dan Roden's Published Works

Published Works

Other Resources About Dan Roden

What Schools Are Affiliated With Dan Roden?

Dan Roden's AcademicInfluence.com Rankings